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CAUSES AND CONSEQUENCES OF GENETIC ROBUSTNESS  
AND FRAGILITY IN HIV-1 PROTEINS 
 
Suzannah J. Rihn, Ph.D. 
The Rockefeller University 2014 
 Genetic robustness describes a capacity to maintain function in the face of 
mutation.  RNA viruses, like human immunodeficiency virus-1 (HIV-1), 
experience extremely high mutations rates in vivo, which contribute to the 
evolvability that permits HIV-1 to evade immune defenses.  However, the 
compact nature of the HIV-1 viral genome, in which small or overlapping proteins 
are often multifunctional and essential, often necessitates a strong pressure to 
conserve functional roles, which is at opposition with immunological pressures to 
diversify.   Under such conditions, and in consideration of the relatively rapid 
replication cycle of HIV-1, natural selection for robustness would be predicted to 
be beneficial.  At the same time, robustness can come at the cost of fitness, and 
it is unclear whether robustness or fitness would constitute the dominant 
selective force in the natural setting. 
Within a given virus, genetic robustness is expected to vary amongst 
proteins, in accordance with specific function.  Therefore, to more accurately 
examine genetic robustness within HIV-1, we selected one protein in which the 
competing needs to both conserve function yet diversify sequence is particularly 
acute.  HIV-1 capsid (CA) is under strong pressure to preserve roles in viral 
 
assembly, maturation, uncoating and nuclear import, but is also under intense 
immunological pressure to diversify, particularly from adaptive immune 
responses.  To evaluate the genetic robustness of HIV-1 CA, we generated a 
large library of random single amino acid substitution CA mutants.  Surprisingly, 
after measuring the replicative fitness of the CA library mutants, we observed 
HIV-1 CA to be the most genetically fragile protein analyzed with such an 
approach, with 70% of random CA mutations resulting in nonviable, replication-
defective viruses (<2% of WT fitness).  While CA is involved in several steps of 
HIV-1 replication, analyses of conditionally (temperature-sensitive) and 
constitutively nonviable mutants indicated that the biological basis for the genetic 
fragility, or lack of robustness, was principally the need to organize accurate and 
efficient assembly of mature viral particles.  
Examination of the CA library mutations in naturally occurring HIV-1 
subtype B populations indicated that all mutations occurring at a frequency >3% 
in vivo had fitness levels that were >40% of WT in vitro.  Moreover, protective 
CTL epitopes were observed to preferentially occur in regions of HIV-1 CA that 
were even more genetically fragile than HIV-1 CA as a whole.  Overall, these 
results suggest the extreme genetic fragility of CA may explain why immune 
responses to Gag, as opposed to other viral proteins, correlate with better 
prognosis in HIV-1 infection. 
To evaluate whether the fragility we observed in CA was unique to CA or a 
general property of HIV-1 proteins, and to more firmly establish causes and 
 
consequences of genetic robustness or fragility, we evaluated the robustness of 
another HIV-1 protein, integrase (IN).  Again, a large library of unbiased single 
amino acid mutants was created.  In contrast to CA, IN appeared comparatively 
robust, with only 35% of 156 single amino acid mutations resulting in nonviable 
viruses.  However, when these nonviable mutants were mapped onto a model of 
the HIV-1 intasome, we noted a striking localization of nonviable mutants to 
certain IN subunit interfaces.  To this end, single mutants affecting both particle 
production and IN expression in virions could be mapped to even more specific 
regions within the intasome model.  Furthermore, after examining the prevalence 
of the IN library mutations in an in vivo cohort of subtype B IN sequences, 
mapping to the intasome helped explain why some in vitro library mutations with 
high fitness (>40% of WT) never occur in vivo, and also revealed that residues 
that are highly variable in vivo are more likely to occur in regions in the intasome 
with more exposed surface area.  Despite the relative robustness of HIV-IN, our 
analyses with an intasome model demonstrate that localized regions of fragility, 
namely certain subunit interfaces, exist. 
Understanding the genetic robustness of HIV-1 is particularly important 
given the continued need for novel therapeutic interventions.  Not only has the 
evaluation of HIV-1 CA and IN robustness revealed particularly fragile regions in 
both proteins, which may prove ideal targets, but comparisons of their genetic 
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Retroviridae and human immunodeficiency virus-1 (HIV-1) 
 The impact of retroviruses in the modern era has been tremendously 
broad and polarized, causing both global pandemic and also contributing 
revolutionary biotechnology.   While not formally named until 1974, the retrovirus 
family had been characterized and implicated in numerous vertebrate diseases 
since the 19th century [1,2].  After the early recognition of Bovine leukosis and 
Jaagsiekte in sheep, key investigations of oncogenic retroviruses in chickens, 
including Rous sarcoma virus (RSV), contributed to Temin’s proviral hypothesis 
in 1964, which was based on his observations that RSV particles containing RNA 
make a DNA copy that is integrated into the host chromosome [2,3,4].  The 
ensuing discovery of reverse transcriptase (RT) in 1970 permitted definition of 
the two distinguishing characteristics of retroviruses, the reverse transcription of 
the single stranded RNA (ssRNA) genome to yield double stranded DNA 
(dsDNA), and the subsequent integration of the dsDNA into host cell 
chromosomes [5,6]. 
Concordant with these defining features, classification of retrovirus genera 
is assigned based on phylogenetic analyses of the highly conserved RT 
sequences (Figure 1).  As Figure 1 indicates, retroviruses are also broadly 
divided by the organization of their genomes into two categories, simple or 
complex [7,8,9].  The simple retroviruses, which include gamma-retroviruses, 








Figure 1.  Retrovirus family phylogeny.  Classification of retroviruses based on reverse 














primarily, of just three major structural genes.  These include: gag, the 
polyprotein which organizes the assembly of viral particles, pol, which contains 
the required viral enzymes for reverse transcription (RT), viral genome integration 
(integrase), and particle maturation (protease, pro, which occurs in a separate 
open reading frame in beta- and delta-retroviruses), and env, which encodes the 
surface and transmembrane portions of the viral envelope.  Complex 
retroviruses, on the other hand, contain the same three essential structural 
genes, but typically include additional accessory or regulatory proteins, which are 
often generated from multiply spliced transcripts.      
 Despite any differences in genome classification, there are other 
commonalities amongst retroviruses.  All retroviruses are enveloped, 
nonsegmented, single-stranded, positive sense RNA viruses.  Retroviruses are 
also comparatively small in size, with genomes typically ranging from 7-13 kb, 
and particles that are generally 80-120 nm in diameter. Furthermore, all retrovirus 
genomes, aside from containing gag, pol, and env, are flanked on either end by 
long terminal repeats (LTRs), which contain essential promoter, poly A signal, 
and TATA components, and through their repeating nature, also help to ensure 
proper reverse transcription.  
 Retroviruses also share a common life cycle (Figure 2).  To summarize 
briefly, viral entry (Figure 2A) initiates with the engagement of the retroviral 
envelope with the specific host cell receptor(s), which triggers membrane fusion 








Figure 2. Illustration of the retrovirus lifecycle.  (A) Steps in the lifecycle that occur during and 
after viral entry. These steps include binding of the retrovirus to the host cell receptor, membrane 
fusion with the plasma membrane (or with endosomes), release of the viral core and subsequent 
uncoating, reverse transcription, entry through the nucleus, and finally, integration of the viral 
DNA into the host genomic DNA. (B) Steps in the lifecycle corresponding to assembly and exit of 
newly made viral particles.   These steps include transcription by RNA polymerase II, splicing and 
export of viral RNA from the nucleus, translation of the viral proteins, RNA packaging and Gag 
assembly, budding, and release from the cell membrane, and finally, virus maturation.  Figure 










Subsequent entry of the viral core into the host cell cytoplasm is followed by the 
disassembly, or uncoating, of the viral core, after which the reverse transcription 
complex (RTC) forms, and the ssRNA is reverse transcribed.  The newly 
synthesized dsDNA genome traverses the cytoplasm and forms a preintegration 
complex (PIC), which permits nuclear entry.  Subsequently, the viral dsDNA is 
integrated into the host genomic DNA to yield the provirus, a process that will 
later be described in far greater detail.  To begin the formation of new retroviral 
particles (Figure 2B), the promoter in the U3 region of the 5’ LTR engages the 
error-prone RNA polymerase II for transcription.  Viral RNA transcripts are then 
spliced, as necessary, and escorted out of the nucleus, often with the aid of 
accessory proteins.  Some of the exported transcripts are translated as viral 
proteins or polyproteins that are prepared for Gag assembly, while the remaining 
full-length RNA transcripts are packaged for inclusion in new particles.  As Gag 
assembly and multimerization completes and viral budding begins, the 
endosomal sorting complexes required for transport (ESCRT) network of proteins 
are recruited to aid in the scission and release of the particle from the cell 
surface.  Finally, cleavage by the viral protease ends the life cycle with the 
formation of a mature retroviral particle. (Basic retroviral characteristics and life 
cycle reviewed in [9,11,12,13,14]). 
 Among the retroviruses, one has become the overwhelming focus of 
intense research.  Human immunodeficiency virus-1 (HIV-1) is one of the 
deadliest human scourges the world has experienced, as infection typically 
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results in acquired immunodeficiency syndrome (AIDS), which is responsible for 
the deaths of an estimated 36 million people [15,16].  As of 2012, a further 35.3 
million individuals were currently living with HIV, indicating that the clinical impact 
of the virus remains tremendous, particularly as effective antiretroviral therapies 
are accessible to just 34% of individuals in the middle- and low-income countries 
where most infected individuals reside [15], and because vaccine strategies have 
thus far proved challenging [17,18].  Overall, this is a relatively modern burden, 
as the first indications of AIDS appeared in 1981![19,20], and the determination of 
HIV-1 (often referenced as HTLV-III in the mid 1980s) as the causative agent of 
AIDS followed in 1983-1984 [21,22,23].  The origins of the AIDS pandemic, 
caused by the HIV-1 group M lineage, arose from a single cross-species 
transmission from simian immunodeficiency virus (SIV) in chimpanzees (Pan 
troglodytes troglodytes with SIVcpz) that occurred in southeastern Cameroon 
around 1910-1930 and spread around Kinshasa [20,24,25,26].  However, several 
additional HIV-1 transmission events between humans and other primates have 
occurred, including non-pandemic HIV-1 group N and perhaps O lineage 
transmissions from SIVcpz, HIV-1 group P lineage transmission from gorillas 
(SIVgor), and a related cross-species transmission from sooty mangabeys 
(SIVsmm) is now known to be the source of HIV-2 [20,24,27,28].    
 Notably, HIV-1, which will form the focus of the research discussed herein, 
is a lentivirus, along with HIV-2 and primate SIVs (Figure 1).  Additional 
nonprimate lentiviruses are divided into four other groups: ovines-caprines, 
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bovines, felines, and equines.  Lentiviruses derive their name (slow, lentus-) from 
their long incubation periods, and share many additional features, including 
chronic and persistent viral replication, macrophage tropism, destruction of 
specific hematologic or immunologic cells, the inclusion of accessory genes in 
the genome, neurologic manifestations, and periods of latency [9,29,30].   
Lentiviruses are also characterized by a common morphology, including a viral 
core with a unique cone or cylindrical shape [9].  While lentiviruses are not 
directly oncogenic like many pathogenic retroviruses, the immune disorders they 
induce can result in oncogenic disorders, such as Kaposi’s sarcoma or 
lymphomas [31,32]. 
 As is true for other primate lentiviruses, the primary host cell receptor for 
HIV-1 is CD4, and this significantly limits the tropism of the virus, as CD4 
expression is generally restricted to macrophages, dendritic cells, and helper T-
cells [33,34].   In fact, the slow decline in the population of CD4+ cells over the 
course of HIV-1 infection contributes to, and defines, the hallmark HIV-1-induced 
immunodeficiency that is AIDS [35].  In addition to CD4, the HIV-1 surface 
envelope (gp120) must also bind one of two co-receptors, either chemokine 
CXCR4 or CCR5 [36,37,38,39].   While most transmitted viruses initially utilize 
CCR5 (R5-tropic), over time many switch to using CXCR4 (X4-tropic), in a 
manner linked to disease progression [40]. 
Not surprisingly, many of the other defining features of HIV-1 involve its 












Figure 3. Organization of the HIV-1 viral genome.  Illustration of the open reading frames 















three structural proteins common to all retroviruses, Gag, Pol, and Env, the HIV-1 
genome also includes two regulatory proteins essential for viral replication, Tat 
and Rev, as well as four accessory proteins, Nef, Vif, Vpu, and Vpr, that can 
modulate viral replication and affect pathogenesis in vivo.  As the nature of the 
work discussed in this thesis includes detailed analyses of the capsid (CA) 
protein, which is part of Gag, and the integrase protein (IN), which is part of Pol, 
these polyproteins will be reviewed in far greater detail in separate introductory 
sections, but basic functions of the other proteins will be summarized.   Env is 
similar to the general retroviral envelope previously described, and consists of 
surface, trimeric gp120, which elicits considerable virus-neutralizing antibody 
responses, as well as transmembrane, trimeric gp41 [42,43].  The regulatory 
protein Tat is primarily involved in nuclear transactivation of the LTR by 
interactions with TAR sequences, and helps ensure proper activation and 
elongation of viral genome transcription [44,45].  Both Tat, and the other 
regulatory protein, Rev, are encoded by multiply spliced mRNAs [16].  Rev is 
involved in regulating viral mRNA expression; it binds the Rev response element 
(RRE) located in env and impacts nuclear export of either unspliced or singly 
spliced RNAs [46,47]. 
 One of the common features amongst the HIV-1 accessory proteins is 
their capacity to act as adapter proteins, as they often bind other host cellular 
complexes in order to target host proteins (frequently antiviral) for degradation, 
generally in an ubiquitin-dependent fashion [48].  To this end, Vif, the viral 
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infectivity factor, partners with cellular proteins (Cul5, elongins B and C, and 
Rbx1) to promote the degradation of antiviral factor APOBEC3G (as well as 
APOBEC3C, 3F, and 3H) [49,50,51,52].  Similarly, viral protein U (Vpu) aids 
virion release through both its interactions with the restriction factor tetherin, in a 
fashion causing tetherin degradation, and through its contribution to the 
degradation of CD4 [53,54].  While the Vpr protein does not target a known 
restriction factor for degradation, it has been speculated that this is likely, and Vpr 
has very recently been suggested to target the host SLX4 complex to promote 
arrest of the cell cycle in the G2/M phase as well as escape from innate immune 
sensing [55].  Vpr may additionally be involved in the activation of transcription, 
induction of cell death, and enhancement of RT fidelity [48,56].  The final HIV-1 
accessory protein, negative factor (Nef), despite its misnomer labeling, is 
reported to be involved in an increasingly large number of functions that primarily 
enhance infectivity, alter replication, and delay immune clearance, but it is not 
essential for viral replication.  Nef’s wide-ranging roles in HIV-1 are known to 
impact: signaling transductions pathways, host major histocompatibility complex-
1 (MHC-1) and CD4 and other protein expression, antigen presentation, cellular 
trafficking, and survival of cells [57,58,59]. 
These descriptions of retroviruses and HIV-1, while basic, provide a 





Genetic robustness and fragility 
One of the most remarkable features of HIV-1, and other RNA viruses, is 
their strikingly high mutation rate.  As Figure 4A demonstrates, the mutation rate 
is higher for RNA viruses than for any other biological entity, with the exception of 
one documented example of a viroid [60,61].   Furthermore, additional evidence 
has shown that the mutation rate for ss(+)RNA viruses like HIV-1 is considerably 
higher than for other RNA viruses, or DNA viruses for that matter (Figure 4B) 
[62].  Given the neutral theory of molecular evolution, which postulates that the 
mutation rate is the sole determinant of the rate of evolution [63], as well as the 
adaptation theory [64,65,66], which also considers mutation rates to be central to 
evolution rates, it is perhaps not surprising that ss(+)RNA viruses have also been 
shown to have higher rates of evolution than other viruses (Figure 4C) [62].  In 
fact, the HIV-1 genome has previously been estimated to evolve approximately 
one million times faster than mammalian DNA [67,68].    
Examination of viral mutation rates and evolvability is of importance in the 
context of HIV-1 and RNA viruses on several fronts.  Mutation rates have already 
been determined to impact everything from pathogenesis in RNA viruses [69,70], 
to drug resistance patterns [71,72], antiviral therapy success [73,74], efficacy of 
vaccines [75,76], and the emergence of new pathogens [77,78].  However, 
despite the simplicity of the neutral theory of molecular evolution, directly 
equating mutation and evolution rates is unrealistic given the complex 




Figure 4. Comparisons of viral mutation and evolution rates.  (A) Evaluation of mutation 
rates, as compared to genome size, for various biological entities.  (B, C) Mutation (B) and 
corresponding evolution (C) rates, as indicated, for the various major virus groups (as defined by 










To better understand this environment and the interplay between mutation 
and evolution, it is helpful to conceive of viral populations as mutant networks 
(Figure 5A).  HIV-1’s use of error-prone reverse transcriptase and non-
proofreading RNA polymerase II provides characteristic low-fidelity replication, 
similar to other RNA viruses, and results in a mutation rate for HIV-1 of 
approximately 1.4-3.4 x 10-5 mutations/nucleotide/cycle [79,80].  This, combined 
with the large population size typical of HIV-1, has been suggested to mean that 
every single point mutation, and some double mutation combinations, could 
theoretically be produced during each replication cycle in an infected individual 
(thus nearly every 1-2 days [81]), leading to an extremely genotypically diverse 
population over time [82].  However, previous work has already determined that, 
in addition to high mutation rates, RNA viruses also have comparatively low 
tolerance to mutation [83].  Therefore, within the framework of a mutant network 
(Figure 5A), some of the randomly introduced mutations will maintain a fitness 
level, or replication competency, which is comparable to the parental sequence 
(illustrated by red circles), while many others will have moderate (green circles) 
or severe (gray circles) fitness defects.  In this way, error-prone replication 
proceeds as an exploration of available sequence space, and large populations 
make for rapid, moderately low-risk travel through this space. 
Still, not all entities, or RNA viruses for that matter, can tolerate mutation to 
the same extent.  Thus, the term genetic robustness can be employed to 





Figure 5.  Viral networks and their dynamics in hosts.  (A) Schematic demonstrating how 
mutations (colored triangles) are acquired from the consensus sequence (gray line) due to the 
characteristic low-fidelity replication in RNA viruses.  The population network indicates how RNA 
virus populations can be illustrated as networks with genetic variants (colored circles) of differing 
fitness that are linked by mutational pathways.  (B) Illustration of how viral networks shown in (A) 
might behave when under selection in a natural host.  The center diagram shows the initial viral 
population, and variants are indicated by circles (colored by fitness) connected by the network 
(black lines).  Overall, an indication is given of how robustness might be impacted by: differences 
in host immune pressures (Host A vs. Host B), the presence of a restriction factor, or replication 
in diverse tissues.  Figure adapted from [82]. 
!!Low-fidelity replication Genotypically diverse population 





[84,85].  More robust proteins or organisms can tolerate higher mutation rates, 
while less robust, or fragile, proteins or organisms are more intolerant of mutation 
and are likely to lose function or to be driven to extinction by high mutation rates.  
Determining genetic robustness typically involves quantification of mutational 
fitness effects for individual mutations, in comparison with wild type fitness.  
Generally, at least in the case of viruses, this is achieved by the introduction of 
random point mutations into the genome and the subsequent measurement of 
the mutation’s effect on replicative efficiency [86,87,88].  However, it is also 
possible to more indirectly measure robustness of viruses by quantifying their 
sensitivity to nucleoside analogues that artificially increase mutation rates [74,89].   
In both cases, (subjectively) large mutational fitness effects are indicative of 
fragility, while smaller fitness effects suggest robustness.  In this way, robustness 
can be calculated for whole entities, such as entire RNA virus genomes, or for 
smaller segments such as proteins or domains.  However, it is expected that 
measurement of robustness for large entities like whole genomes may mask the 
variation in robustness that occurs amongst individual proteins or regions within 
that genome, in accordance with the specific functions of the individual proteins 
or domains. 
 At present, there are no known absolute determinants of an entity’s 
genetic robustness.  Instead genetic robustness of an entity like HIV-1, or its 
proteins, likely depends on a variety of specific characteristics, primarily 
concerning individual functions and the natural host environment.   
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Correspondingly, the robustness of either distinct viruses, or proteins or domains 
within a virus, can vary widely, as the extreme robustness of the HIV-1 LTR, in 
which data indicated that 100% of point mutants maintained WT-like levels of 
infectiousness![90], and the relative fragility of HIV-1 protease![91], in which just 
46% of mutants maintained viability, illustrate.   To this end, it has been 
previously theorized that proteins that perform multiple or complex functions that 
are highly dependent on structure, such as enzymes (like protease), should tend 
to be more genetically fragile and display greater sequence conservation than 
those that do not [92].  At the same time, population genetics theory predicts that 
robustness is more likely to be selected for when mutations rates are high, as it 
should be advantageous [84,92].  Nevertheless, previous data has also shown 
that robustness can vary even amongst whole virus genomes with high mutation 
rates, as only 20% of single mutations in bacteriophage ΦX174 were considered 
lethal [87], while more than twice as many, 41%, of point mutations in tobacco 
etch potyvirus had the same effect [93].  
As Figure 5B demonstrates, the host environment also has a large 
influence on the available sequence space a population can utilize, and, thereby, 
its overall robustness.  Specific host features including interactions with 
restriction factors or other cellular factors, tissue tropism, and other immune 
pressures can impact the fitness of individual mutations, which in turn impact the 
greater fitness landscape and the further exploration of sequence space [82].  In 
the case of HIV-1, adaptive immune responses play a particularly significant, 
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hostile and changing environmental role.  These immune responses can take the 
form of antibodies that target proteins displayed on the surface of virions, or 
cytotoxic lymphocytes (CTLs) that target epitopes in a number of viral proteins.  
As a result, some viral proteins, even those that should exhibit genetic fragility as 
a reflection of their complex or essential nature, are placed under strong 
evolutionary pressure to diversify in sequence, despite fitness costs, in order to 
evade adaptive immune responses.  Under these conditions, otherwise fragile 
proteins might evolve higher robustness.  Ultimately, the pressures impacting 
robustness can be narrowed to two broadly competing categories: those inherent 
pressures imposing conservation of sequence in order to preserve specific and 
essential functions, and opposing pressures to diversify sequence in order to 
avoid a hostile host environment.  However, the outcomes regarding any 
potential trade-off between robustness and fitness are not established, so it is 
unclear whether fitness, or acquisition of robustness, would constitute a dominant 
selective force on a viral protein in the natural setting.  It should be noted, 
nevertheless, that initial examinations have suggested that, at least under certain 
circumstances in viral populations, high robustness can be favored at the 
expense of high fitness, indicating robustness may be the more potent selective 
force [94,95,96].  
Intriguingly, both theories and experiments concerning the evolution of 
robustness have yielded a common observation: ‘survival of the flattest’ 








Figure 6. Lethal mutagenesis and the survival of the flattest.  Red indicates populations with 
fast replication, but that are genetically fragile, while the blue shows ‘flat’ populations that have 
slower replication, but are more robust.   The panels on the left show populations with either high 
or low mutation rates, and the right panels demonstrate the expected distributions of the two 
types of populations under the different mutation conditions.  When mutation rates are low, the 
fitter population will always successfully outcompete the ‘flatter’ population.  However, this can be 
reversed when mutation rates are high, as the tops of the high narrow peak will display the 
highest fitness, but the other population will have less variance in fitness due to its increased 







landscape model [99], these results have indicated that at low mutation rates, 
quickly replicating populations (in red, high fitness populations with little genetic 
distance) are expected to always outcompete the slower replicating populations 
(in blue, populations with more genetic distance) that have a low, flat peak and 
higher robustness [96].  However, this situation can be reversed at high mutation 
rates (Figure 6, bottom panels), when the flatter population with less variance in 
fitness may be more adaptive.  Consequently, for HIV-1, with its high mutation 
rate, a flatter, more robust population with greater genetic variance might be 
expected to be favored over more fit but fragile populations. 
At the same time, a number of studies, using either mutagenic nucleoside 
drugs or variant RNA-dependent RNA polymerases, have shown that the 
mutation rate in RNA viruses is extremely close to a catastrophic error rate that 
would lead to extinction [100,101,102], indicating there may be some degree of 
fragility in these populations.  These ‘lethal mutagenesis’ studies have sought to 
determine the threshold at which the mutation rate becomes biologically 
intolerable and viral infectivity is eliminated.  From a therapeutic point of view, 
examination of lethal mutagenesis for HIV-1 offers great potential as an 
alternative to antiretroviral treatments susceptible to drug resistance [73].  This is 
especially true given that natural hosts contain their own source of 
hypermutagenesis in APOBEC3G (normally counteracted by Vif)![103,104,105].  
Hence, examination of the genetic robustness or fragility of HIV-1 and its 
components may contribute to therapeutic vaccine and drug development efforts 
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not only through the revelation of regions remarkably sensitive to mutation, but 
also through discovery of how close HIV-1 may already be to its own error 
catastrophe.  
HIV-1 capsid 
 As previously mentioned, evaluation of the robustness of whole viral 
genomes can mask significant variability amongst proteins or domains within, in 
accordance with specific functions or host pressures.   For this reason, evaluation 
of a single essential protein in HIV-1, such as capsid (CA), may provide a more 
thorough, albeit localized, representation of genetic robustness and its causes 
and consequences.  Capsid is a particularly appropriate protein in which to 
measure robustness as it experiences competing needs to both preserve 
function, yet diversify sequence, in an acute manner.  As a critically important 
protein, it is placed under intense selective pressure to maintain its structure and 
perform several functions.  Conversely, as a highly expressed, immunologically 
visible protein, CA also assumes a competing pressure to diversify its sequence, 
and it is unclear how these competing pressures might impact the protein’s 
genetic robustness. 
 Among the unique features of HIV-1 CA are its multifunctional nature and 
its presence in different structural orientations—it exists as both a domain within 
the Gag precursor polyprotein during particle assembly, and as an autonomous 
protein in mature virions (Figure 7) [11,106,107].  As part of Gag, CA is 








Figure 7. Diagram of HIV-1 assembly.  (A) Legend indicating the identity and corresponding 
color of the respective proteins comprising Gag or Gag-Pro-Pol.  Capsid is shown in the darker 
green color. (B) Outline of the steps that occur during assembly at the plasma membrane and in 
subsequent viral budding and maturation.  (C) Sequential illustration of the HIV-1 Gag 










at the 3’ end (Figure 7A).  Gag also includes nucleocapsid (NC), spacer peptide 2 
(SP2), and p6, which follow SP1 sequentially, whilst Gag-Pro-Pol additionally 
contains the viral enzymes (protease, reverse transcriptase, and integrase) at the 
3’ end of Gag (Figure 7A) [108].  In the initial stages of virion morphogenesis, 
Gag molecules assemble, largely through the targeting of MA, at the plasma 
membrane, along with additional Gag-Pro-Pol molecules (Figure 7B), to drive the 
formation of roughly spherical virions, which contain radially arrayed Gag 
molecules that bud through the plasma membrane [109,110].  During and after 
subsequent viral budding, protease is activated and catalyzes cleavage of Gag in 
five positions (Figure 7C), causing extensive morphological transformations and 
the transition from an immature to mature viral particle![14].  As a result, the 
liberated CA protein forms a distinctive conical capsid that encapsulates the 
nucleocapsid-genomic RNA complex [111,112]. 
 Like all retroviral capsids, the 231 amino acid (aa) HIV-1 CA molecule is 
composed of two domains: the N-terminal domain (NTD), which contains the first 
146 aa, and the C-terminal domain (CTD), which contains the remaining 85 aa.  
The structure of the NTD comprises an N-terminal β hairpin followed by 7 α 
helices, while the CTD consists of 4 α helices and a final C-terminal unstructured 
region of 11 residues (Figure 8B, 8C and 8D in white) [113,114,115].  In between 
the NTD and CTD lies a small interdomain linker region (residues 146-150).   
Other noteworthy regions in CA include the major homology region (MHR, 




Figure 8. HIV-1 CA structures. (A) A slab view illustrating an experimental map of CA hexamer 
formation, with the CTD in blue, the NTD in green, and a red line outlining the hexamer. (B) A 
pseudoatomic model of the full-length CA monomer.  Individual helices and loops are labeled 
accordingly.  (C, D) External views of the CA hexamer, in which a single monomer is outlined in 
white.  (E) Stereoview of the complete CA fullerene cone, comprised of approximately 1,056 
subunits, and including 12 pentameric declinations.  The pentamer structures are shown in 
yellow, while the hexamer NTD is in orange and the hexamer CTD is in blue.  Figure constructed 





found in all retroviruses [118] and the likely binding site of host protein ABCE1!
[119], and a loop (NTD residues 85-93) which binds the cellular protein 
cyclophilin A (hereafter referred to as the cyclophilin binding loop) [120]. 
 As will later become evident, the structure of CA is particularly relevant to 
its robustness, and thus its components warrant further description.  The mature 
HIV-1 capsid includes ~1056 CA monomers arranged in a hexameric lattice 
(Figure 8A, and 8E in orange/blue) interspersed with 12 pentameric declinations 
(Figure 8E, in yellow) which allow the viral capsid to form a fullerene cone (Figure 
8E) [111,117].  Within the hexameric lattice (Figure 8A, C, E), the NTD creates 
the hexamer ring shape (Figure 8A, C in green, 8E in orange) while the CTD 
forms the dimeric linkers that link neighboring hexamers (Figure 8A, C, E in blue) 
[116,121].  Correspondingly, there are three primary protein-protein interactions 
in the mature capsid lattice: NTD-NTD, CTD-CTD, and NTD-CTD.  The NTD-NTD 
hexamerization interface is mediated by a six-fold symmetric interface involving 
helices 1, 2, and 3 (to form an 18-helix bundle) [116,122]. The homodimeric CTD-
CTD interface links the hexameric building blocks and occurs through a parallel 
association at helix 9 (around residue 185), although other CTD regions likely 
contribute to the stability of this arrangement [115,123].  Finally, the hexamer is 
reinforced through stabilizing intermolecular NTD-CTD interactions, primarily 
involving the extended side chains from CTD helix 8 which maintain interfaces 
with NTD helices 3-4 (and the intervening loop) [123,124,125].  Protein 
interactions in the relatively rare pentameric declinations (Figure 8E, in yellow) 
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are similar to those found in hexamers, with only subtle rearrangements in the 
subunit interactions [117].  Disruptions to any of the interaction interfaces are 
likely to disrupt proper capsid assembly, causing irregularly shaped capsids and 
less- or noninfectious particles [123].  Additionally, the dramatic differences 
between the conformations of immature and mature capsid suggest the presence 
of additional protein-protein interfaces and interactions not found in the mature 
capsid, and if these were disturbed, would also be likely to negatively impact 
assembly [110].  
 In addition to contributing a major structural role, CA determines several 
other biological properties of HIV-1.  For instance, HIV-1 capsid has been 
demonstrated to be the key determinant that permits HIV-1 to infect non-dividing 
cells [126,127].  Other work has identified capsid as having a number of genetic 
or physical interactions with various host proteins, including karyopherin β 
transportin-3 (TNPO3) [128], nucleoporin 153 (NUP 153) [129,130], nucleoporin 
358 (NUP358)/RanBP2 [131], and cleavage and polyadenylation factor 6 
(CPSF6) [132].  Moreover, the interactions between HIV-1 capsid and host 
protein cyclophilin A are also known to influence nuclear import and subsequent 
integration site selectivity, as well as replication efficiency, in a cell type 
dependent manner [131,133,134,135]. 
 Capsid is also a major target of intrinsic, innate, and adaptive immune 
defenses.  Intrinsically speaking, capsid has recently been shown to be a 
determinant of HIV-1’s sensitivity to the antiviral factor Myxovirus resistance 2 
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(Mx2) [136], an interferon-induced, dynamin-like GTP-ase that can inhibit early 
steps of HIV-1 infection in vitro.  Reports of CA residues affecting Mx2 restriction 
of HIV-1 have thus far been limited to CA residues within the cyclophilin binding 
loop (and one other residue, N57, previously reported to affect HIV-1 infection of 
non-dividing cells [127]) [136,137,138], however the likelihood that other residues 
within CA determine sensitivity to Mx2 will be further explored in the results 
section.  CA is also targeted by antiretroviral factor TRIM5α, and is thereby a 
major determinant of its restriction capacities [139,140].  Alternatively, as a target 
of the innate immune defenses, CA is believed to be detected by undefined 
sensors in dendritic cells [141].   
 HIV-1 CA is also under pressure from adaptive immune forces 
[142,143,144,145].  In particular, host human leukocyte antigen (HLA)-associated 
CD8+ cytotoxic T lymphocyte (CTL) responses to HIV-1 infection are significant 
determinants of viral control [146,147], and there is an association between Gag- 
and capsid-specific CD8+ T-cell responses and the in vivo viral burden [148].  
Moreover, the emergence of viral ‘escape’ mutations in CA has been shown to 
result in higher viremia in infected patients [149,150].  However, CA escape 
mutations often incur significant fitness costs, which may be subsequently 
compensated for by secondary mutations in CA, or result in reversion when 
immune pressure is lifted [144,150,151]. 
 A large number of earlier studies have mutated HIV-1 capsid with the aim 
of elucidating the importance of particular domains, regions, and residues in CA 
functions.  Such targeted mutagenesis studies have largely relied upon insertion 
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[152], deletion [153], or alanine or proline scanning [154,155].  While certainly 
informative of the impact a single residue mutation could have on infectivity, core 
morphology, or the like, these studies are not necessarily predictive of the 
phenotypes that might result from naturally-occurring mutations that arise through 
errors during reverse transcription or from RNA polymerase II.  In our CA 
mutagenesis approach, we will attempt to utilize more unbiased means of 
inducing mutation, on a far larger scale, and in so doing, measure the genetic 
robustness of CA and determine it’s biological causes and implications.  These 
are, of course, deeply rooted in the many functions and interactions of HIV-1 
capsid. 
HIV-1 integrase 
 To establish whether any trends observed from evaluation of the genetic 
robustness of HIV-1 capsid might be unique to CA, or a larger reflection of the 
robustness of the entirety of HIV-1, it seemed prudent to evaluate the genetic 
robustness of another important HIV-1 protein.  HIV-1 integrase (IN), like HIV-1 
CA, is a highly conserved, essential, multifunctional protein, and is the enzyme 
responsible for the integration of the viral genome into the host chromosome.  
Within the framework of the viral life cycle, IN functions just after reverse 
transcription, and is responsible for two necessary catalytic activities, 3’ 
processing and DNA strand transfer.  It has previously been hypothesized that 
the requirements needed to fulfill enzymatic catalytic activities like these, which 
involve adopting and changing tertiary structures in subtle, flexible ways, may 
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mean enzymes are particularly sensitive to mutation [92].  The relatively high 
degree of conservation in integrase, especially within the protein’s catalytic core 
domain [156], also suggests IN may be not be tolerant of mutation. 
 While the crystal structure for the functional HIV-1 IN unit, the intasome, 
has not yet been determined, significant insight exists regarding the domain 
structures and functions in the 32 kDa, 288 amino acid HIV-1 IN protein (Figure 
9A).  At the most N-terminal end, the roughly 49 amino acid N-terminal domain 
(NTD) adopts a helix-turn-helix fold, contains a highly conserved HH/CC zinc 
binding domain (at residues 12, 16, 40, 43, Figure 9A), and contributes to 
stabilization, multimerization, and DNA binding [157].  The adjacent catalytic core 
domain (CCD), residues 50-212 (also sometimes reported as 59-202), is 
responsible for both 3’ processing and strand transfer reactions, and also 
contributes to multimerization and both viral DNA (vDNA) and host target DNA 
binding [158,159].  This domain adopts a RNase H fold, and contains a D, D(35)-
E motif that binds divalent metal ions, largely Mg2+ [159,160].  At the C-terminal 
end, the C-terminal domain (CTD), which includes residues 213-288 (or 223-
270), adopts a beta barrel resembling an Src homology 3 (SH3)-type fold, is 
significantly involved in binding to host cell target DNA, and like the other 
domains, also contributes to multimerization [159,161,162].  Ultimately, the three 
domains in each monomer come together to form a tetramer comprised of a 




Figure 9. Overview of HIV-1 IN, the intasome, and integration. (A) Organization of the HIV-1 
IN protein, indicating the approximate individual domains, their sizes, and the notable elements 
within. (B) First published model of the HIV-1 intasome, with the image on the left showing the full 
IN tetramer.  The right image indicates the IN dimer and the domains within.  (C) Schematic of the 
retroviral integration processes, indicating the retroviral nucleoprotein complexes formed during 








(Figure 9B).  The publication of the crystal structure of the prototype foamy virus 
(PFV) intasome has provided further insight into the possible arrangement of 
HIV-1 IN’s three domains within the tetramer, and has suggested how the 
domains might contribute to vDNA and host DNA binding [166,167].  
Furthermore, the PFV crystal structure, and the knowledge it has conveyed, has 
led to new, improved HIV-1 intasome models [164,168] (Figure 9B). 
 The catalytic activities of integrase begin within the confines of the reverse 
transcriptase complex (RTC) in the host cell cytoplasm (Figure 9C).  After 
reverse transcriptase copies the single-stranded viral RNA genome into a linear 
double-stranded DNA molecule that contains a copy of the LTR at each end, 
multimeric (likely tetrameric) integrase binds the newly synthesized LTR ends to 
form the retroviral intasome complex known as the stable synaptic complex 
(SSC) [165,169] (Figure 9C).  During the subsequent 3’ processing reaction, IN 
processes each LTR end at a location adjacent to an invariant CA dinucleotide, 
so as to yield CAOH 3’-hydroxyl groups, which will later serve as the nucleophile 
in the second reaction [170,171].  This 3’ processing reaction results in an 
intasome configuration known as the cleaved donor complex (CDC).  At the 
same time, the viral replication intermediate now has the capacity to initiate DNA 
strand transfer activity, and this marks a transition in the viral nucleoprotein 
complex nomenclature from the RTC to the pre-integration complex (PIC).  Upon 
nuclear entry and the location of a suitable target site on the host cell chromatin, 
tetrameric IN uses the exposed 3’ oxygen atoms to cut phosphodiester bonds on 
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opposing strands of the target DNA (tDNA), in a staggered fashion, and it also 
simultaneously joins the viral DNA ends to the tDNA’s 5’ phosphates 
[172,173,174] (Figure 9C).  The initiation of the DNA strand transfer reaction, in 
which the CDC engages the tDNA, leads to the formation of the target capture 
complex (TCC), and the subsequent integration of the viral DNA 3’ ends results 
in the formation of the strand transfer complex (STC).  Finally, host cell enzymes 
repair the unjoined viral DNA 5’ ends, to yield the fully integrated provirus. 
Determination of these enzymatic functions of IN has often involved 
mutagenesis of IN.  Scanning and site-directed mutagenesis work has been 
critical to demonstrating the structural and functional contributions of both whole 
subunits and individual residues within IN [175,176,177,178,179,180,181].  
Furthermore, deletion mutants of various subunits, or parts thereof, have also 
proved individual domain contributions to both HIV-1 IN catalytic activities, and 
initially indicated the likelihood that IN forms a functional multimer [182,183,184].  
Overall, however, mutations in IN have typically been divided into two classes 
[185].  Class I mutants are those that directly affect either of the enzymatic 
activities of IN (which in turn, affect infectivity), while class II mutants reduce 
infectivity at a stage other than integration.  In some cases, class II mutants have 
also been shown to yield virions with abnormal cores [186].  Despite the large 
quantity of IN mutagenesis studies probing specific function, no study has 
randomly or extensively mutagenized the entirety of HIV-1 integrase yet, nor has 
any study sought to evaluate its genetic robustness.    
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 Mutagenesis of IN has also helped demonstrate interactions between IN 
and its cellular co-factors.  Like CA, IN is known to interact with a number of host 
proteins, some of which are required for efficient levels of infectivity.  Perhaps the 
most important of these co-factors is the essential lens epithelium-derived growth 
factor (LEDGF/p75), which helps direct integration into chromatin sites within 
genes, or regions with active transcription units [187,188].  Certain mutations 
within IN, particularly in the C-terminal region of the catalytic core domain, have 
the ability to disrupt the interaction between IN and LEDGF and correspondingly 
impact infectivity [189].  HIV-1 integrase is also believed to interact with IN 
interactor 1(INI1)/hSNF5 [190], as well as the cellular co-factor transportin SR-2 
(TRN-SR2, or TNPO3), a karyopherin which helps mediate nuclear import [191], 
amongst other less confirmed interactions [192,193].    
 Despite its interactions with the cellular environment, and unlike HIV-1 CA, 
HIV-1 IN does not appear to be the target of intense, or, rather, successful 
immune responses.  At present, there are no known intrinsic or innate immune 
defenses that target IN.  Furthermore, while certain human leukocyte antigen 
(HLA)-associated CD8+ cytotoxic T lymphocytes (CTL) epitopes to CA can be 
protective, and correlated with reduced viral loads, replication capacity, or non- or 
delayed progression to AIDS [194,195], the same does not appear to be true for 
integrase [148].  Integrase can be a target of CTL responses, including some 
associated with protective HLA class I alleles [196,197,198], and individuals with 
reduced viral loads can very occasionally show T-cell responses against 
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integrase [199].  Nevertheless, more conclusive evidence suggests that there is 
no substantial immune-driven attenuation of integrase during HIV-1 infection 
[200]. 
As anti-retroviral treatments for HIV-1 have progressed, integrase has 
become an increasingly important target of HIV-1 therapeutic treatment.  In fact, 
a multitude of integrase inhibitors targeting the individual integration steps have 
been developed, and these can be divided into six general classes: DNA-binding 
inhibitors, 3’ processing inhibitors, nuclear translocation/import inhibitors, strand 
transfer inhibitors, gap repair inhibitors, and the allosteric inhibitors [156,201].  At 
present, the integrase strand transfer inhibitors (INSTIs), raltegravir, elvitegravir, 
and dolutegravir, have been the most clinically successful class of inhibitors 
[165,202].  However, the susceptibility of these drugs to resistance mutations has 
meant that the search for new integrase inhibitors continues [202].  Work has 
increasingly focused on the allosteric integrase inhibitors (ALLINIs), which may 
work by competing with LEDGF/p75 for binding to integrase, thereby disrupting 
integrase assembly with viral DNA and inhibiting enzyme function [203].  
Furthermore, recent work has shown that administration of a long-acting 
integrase inhibitor can protect macaques from infection by a simian/human 
immunodeficiency virus [204].  Evaluating the genetic robustness of HIV-1 IN 
therefore seems a particularly worthy task, as it presents the possibility of 
uncovering regions of vulnerability or fragility that could prove valuable to novel 
inhibitors or other therapeutic treatments.  Moreover, comparison of IN 
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robustness with that of CA should reveal more about how the competing 
pressures to maintain sequence for function preservation, and also to diversify 






















II. MATERIALS AND METHODS 
Plasmids 
Throughout the described work, production of infectious HIV-1 was 
achieved using derivatives of a proviral plasmid previously used in our laboratory, 
pNHG (accession: JQ585717) [205].  Containing full-length HIV-1, with the 
exception of Nef, which is replaced with EGFP, pNHG expresses NL4.3 GagPol 
and HXB2 envelope (the remaining portions being previously derived from 
pNL/HXB and R7/3/GFP [206,207]).  All of the work done to construct the CA 
mutant library and evaluate its genetic robustness was done with a derivative of 
pNHG, pNHGcapNM (accession: JQ686832), created by Sam Wilson [208].  
Almost identical to pNHG, pNHGcapNM differs only in that it contains three 
additional restriction enzyme sites, NotI and MluI that roughly flank the capsid 
protein, and a SpeI site that lies around the middle of capsid.  These sites were 
created through synonymous substitutions, with the NotI site added in matrix 
approximately 36 nucleotides 5’ to capsid, while the MluI site lies within capsid, 
approximately 12 nucleotides from its 3’ end.  
 Work done to synthesize and characterize the HIV-1 integrase mutants 
was done with a similar derivative of pNHGcapNM, pNHGintBS.  To create this 
proviral plasmid the first required step was to eliminate the SpeI site in capsid of 
pNHGcapNM.  This was done by amplifying the region between the NotI and MluI 
sites, using primers with overlapping sequence that eliminated the SpeI site in a 
synonymous fashion (sense primer: 5’- CCA AGG GGA AGT GAC ATA GCA 
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GGA ACT ACG AGT ACC CTT CAG GAA CAA ATA GG -3’ and antisense 
primer: 5’-CCT ATT TGT TCC TGA AGG GTA CTC GTA GTT CCT GCT ATG 
TCA CTT CCC CTT GG -3’).  Using the overlapping PCR scheme, the two 
products from a first round of PCRs (the NotI-antisense primer product and the 
sense primer-MluI product) could be used as templates with external primers 
incorporating the NotI and MluI sites in another PCR reaction, after which the 
final PCR product was gel-purified and cloned back into pNHGcapNM.  Next, it 
was necessary to create the new BstBI and SpeI sites that could flank integrase.  
Creation of the BstBI site was done using a similar overlapping PCR scheme, 
with amplification of a region between MluI and EcoRI sites.  Again, utilizing 
synonymous nt substitutions to create the BstBI site (sense primer: 5’- GGT TGG 
TCA GTG CTG GAA TTC GAA AAG TAC TAT TTT TAG ATG G -3’ and 
antisense primer 5’- CCA TCT AAA AAT AGT ACT TTT CGA ATT CCA GCA 
CTG ACC AAC C -3’), two products from a first round of PCRs (containing a 
MluI-antisense primer product and a sense primer-EcoRI product) were weaved 
together with external primers including the MluI and EcoRI sites.  Following gel 
purification of the final PCR product, it was cloned back into the pNHGcapNM 
lacking SpeI, using the MluI and EcoRI sites.  Addition of a new SpeI site was the 
final step to completing pNHGintBS.  Once more, the overlapping PCR scheme 
was used, with amplification of the region between MluI and EcoRI sites.  
Synonymous nucleotide substitutions were used to create the SpeI site (sense 
primer: 5’- GGA TTA ACA CAT GGA AAA GAC TAG TAA AAC ACC ATA 
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TGT ATA TTT CAA GGA AAG C -3’ and antisense primer: 5’- GCT TTC 
CTT GAA ATA TAC ATA TGG TGT TTT ACT AGT CTT TTC CAT GTG TTA ATC 
C -3’), such that products from a first round of PCRs (containing the MluI-
antisense primer product and a sense primer-EcoRI product) were used as 
templates that could be weaved together with external primers including the MluI 
and EcoRI sites in a second reaction.  The final PCR product was then gel-
purified and cloned into the pNHGcapNM containing the BstBI site (and the 
eliminated SpeI site in capsid) using the MluI and EcoRI sites.  As a result, 
pNHGintBS was created (from pNHGcapNM), so that a BstBI restriction site is at 
the 5’ end 9 nt outside integrase (in reverse transcriptase) and a SpeI site is at 
the 3’ end 15 nt outside integrase in Vif. 
 The final plasmid used in the described work is pNL4.3 Pr- (sometimes 
referred to just as Pr-), which has also been previously used in our lab [209].  
This plasmid is a derivative of pNL4.3 (NIH AIDS Research and Reference 
Reagent Program, Catalog No. 114), in which protease is inactive, due to the 
presence of a point mutation in the protease active site [209].  The capsid 
mutants used in this plasmid were digested from pNHGcapNM and cloned 
directly into pNL4.3 Pr- using compatible NotI and MluI sites found flanking 
capsid in each plasmid. 
Construction of CA and IN mutant libraries 
Construction of the unbiased CA mutant library was completed by Sam 
Wilson using a low fidelity PCR approach.  The Genemorph II random 
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mutagenesis kit (Agilent) was used with the following oligos: sense – 5’ –GTA 
AGA AAA AGG CAC AGC AAG CGG CCG CTG - 3’ and antisense 5’ – CTT 
GGC TC A TTG CTT CAG CCA AAA CGC GTG - 3’.  The resulting PCR product 
was cloned using a TOPO TA Cloning Kit and then plasmid DNA was extracted 
from approximately ~1x104 pooled, insert-positive colonies.  Following 
sequencing of the amplicon from 20 clones, in order to obtain a preliminary 
estimate of the mutagenesis frequency, the pooled plasmid DNA was digested 
using NotI and MluI, and the pooled CA-library insert was subcloned into 
pNHGcapNM (Figure 10A).  The NotI and MluI digested proviral plasmid had 
been prepared in advance and generated >200-fold fewer colonies when ligated 
without insert than when ligated with insert.   Additionally, representative 
restriction digests indicated that aberrant restriction patterns, which could be 
caused by recombination, occurred at a frequency of only 1-2% of clones.   
Finally, proviral plasmid DNA was extracted from individual cultures derived from 
1056 colonies and subjected to sequencing and further analysis.  For the single 
mutants listed in Tables 1 and 2, proviral plasmid DNA was freshly isolated, re-
sequenced and analyzed by NotI and MluI restriction digest. 
Creation of the IN mutant library was completed in a manner similar to that 
done for the CA mutant library.  As before, the Genemorph II random 
mutagenesis kit (Agilent, Cat. No. 200550) was utilized, this time with the 
following oligos precisely flanking IN: sense 5’ – GGA AAT GAA CAA GTA GAT 
GGG TTG GTC AGT GCT GGA ATT CGA AAA GTA CTA – 3’ and antisense 5’ – 
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GCT TTC CTT GAA ATA TAC ATA TGG TGT TTT ACT AGT CTT TTC CAT 
GTG TTA – 3’, in several separate reactions with varying amounts of template 
pNHGintBS (400-700 ng), in order to determine the template quantity providing 
the optimal number of single residue mutants.  Both the mutagenized PCR 
products and the proviral plasmid pNHGintBS were then digested with BstBI and 
SpeI, ligated, and cloned (Figure 29A).  Cloning in pNHGintBS without insert 
generated >500-fold fewer colonies than cloning with the mutagenized insert.  To 
ensure the appropriate mutagenesis frequency, preliminary amplicon sequencing 
was done for approximately 285 mutagenized plasmid clones with varying 
template quantities (400, 500, 600, or 700 ng).  During subsequent production of 
the library under the conditions yielding the highest number of single nucleotide 
changes (400 ng template), DNA was extracted from individual cultures derived 
from ~768 colonies.  Amplicon sequencing then revealed which mutant clones 
contained only a single amino acid mutation, and were suitable for inclusion in 
the library.  Final library proviral plasmid DNA was then freshly isolated for the 
single IN mutants, and subjected to analysis by restriction digest using BstBI and 
SpeI, at which point ~2% of clones were removed for evidence of recombination.   
Cell lines and transfection 
 The 293T adherent human cell line was maintained in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 
gentamicin.  Suspension cell lines used in this work were maintained in Roswell 
Park Memorial Institute medium (RPMI-1640), also supplemented with 10% fetal 
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calf serum and gentamicin, and these included MT-4 cells and also a variety of 
other MT-4 lines expressing species variants of the Mx2 protein (either human 
(Hs) macaque (Mac), African Green Monkey (AGM), ovine, or canine).  Those 
MT-4s with variants of Mx2 were made by Sam Wilson and Idoia Busnadiego, 
and were generated by transductions with modified LKO-derived lentiviral vectors 
followed by selection with 2 μg/ml puromycin (Sigma).  Expression of Mx2 
variants in these cell lines was induced by overnight treatment with 125 ng/ml 
doxycycline hyclate (Sigma), prior to viral challenge. 
 In transfection experiments, 293T cells were plated at 2.5 x 104 cells/well 
in 96 well plates or 1.7 x 105 cells/well in 24 well plates.  To measure the effects 
of either CA or IN mutations, transfections were done the following day using 4 
μg polyethylenimine (PEI, Polysciences) per μg of DNA, and either 100 ng (96 
well plates) or 500 ng (24 well plates) of the WT (NHGcapNM or NHGintBS) or 
NHGcapNM or NHGintBS mutant plasmids, or 500 ng of the pNL4.3 Pr- mutants 
(all in 24 well plate experiments).  
 For the temperature-sensitive experiments, plates for all transfection 
experiments were placed at 35, 37, or 39.5°C, as indicated, immediately upon 
addition of the transfection mixture.      
Primary cells 
Peripheral blood mononuclear cells (PBMCs), CD4+ T cells, and 
macrophages were isolated from buffy coats (from anonymous healthy donors, 
purchased from the New York Blood Center) using a Ficoll gradient (with 
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centrifugation at 1500 rpm, for 30 minutes, without brake).  Bulk PBMCs were 
isolated, and washed in RPMI by centrifugation three times.  Primary CD4+ T 
cells were extracted directly from buffy coats using negative selection via the 
RosetteSep Human CD4+ T-cell enrichment cocktail (Stemcell Technologies, 
#15062), also followed by centrifugation using a Ficoll gradient, as well as 2 
RPMI washes.  Macrophages were grown from a subset of the isolated PBMCs 
by allowing the PBMCs to adhere to plastic plates and treating them with 100 
ng/ml of granulocyte/macrophage-colony stimulating factor (GM-CSF) for 96 
hours prior to infection.  All primary cells were maintained in RPMI supplemented 
with 10% FCS, L-glutamine, and penicillin/streptomycin.  Activation of PBMCs 
and CD4+ T cells was achieved by the addition of phytohemagglutinin (PHA) at 5 
μg/ml for 72 hours prior to infection, with addition of 25 U/ml of interleukin-2 (IL-2) 
at the time of infection. 
Viral replication and infectivity assays 
 Relatively similar protocols were used to evaluate genetic robustness in 
CA and IN through replication and infectivity assays.  Therefore, unless 
specifically ascribed to one protein, the referenced assays were used on both IN 
and CA mutants. 
 In order to generate viral particles, 293T cells were transfected with the 
indicated proviral plasmids and given fresh medium 16 hours later.  At ~ 48 hours 
post-transfection, cell supernatants were collected and filtered (0.22 μm).  For the 
single cycle assay, infectivity was measured using MT-4 cells that were seeded 
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in 96 well plates at 4 x 104 cells per well and inoculated with a volume of filtered 
supernatant that was equivalent to an MOI of ~1 for the WT viral clone.  At 16 
hours post-infection dextran sulfate was added at 100 μM in order to limit 
replication to a single cycle, and cells were fixed in 4% paraformaldehyde (PFA) 
48 hours after infection.  Additionally, for temperature-sensitive mutants, the 
same single cycle infectivity assay was used, but viral production (and 
sometimes infection) occurred at 35, 37, or 39.5°C, as indicated in figure 
legends. 
 For spreading replication assays, MT-4 cells seeded in 96 well plates at 2 
x 104 cells per well were inoculated with a much smaller volume of supernatant, 
equivalent to an MOI of ~0.01 for the WT viral clone, and fixed in 4% PFA at 
around 80 hours post-infection.  FACS analysis for all infectivity and replication 
assays was carried out using a Guava EasyCyte instrument, and the percent of 
infected cells was determined by the number that were GFP+. 
 Some of the temperature-sensitive CA mutations (used in Figures 16, 17, 
and 18) that were originally detected in viability screens (as part of analysis of 
Figure 11) were double or triple mutants, and are therefore not listed amongst CA 
mutants evaluated for fitness in Tables 1 and 2.  To isolate single residue 
mutations responsible for the temperature-sensitive phenotype, CA mutants 
encoding each of the following individual substitutions were generated from 
double or triple mutants: S4C, L189M, I91F, Q6P, A78V, I15M, A78V, I15M, 
A78T, S16T, T48A, S33C, A92V, I91N, D163E, I91V, I124T, M96T, R100S, 
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Q112L, R132G, R167Q, M214L, AND K227I.  All of these CA mutants, along with 
other CA mutants identified in temperature-sensitive and viability screens, were 
evaluated for the temperature-sensitive phenotype, and those 11 mutants with 
the greatest effect were included in Figures 16-18. 
 For the CA mutant screen examining Mx2 sensitivity, purified plasmid DNA 
was used from most CA mutants considered viable (>2% WT fitness) in the 
single cycle infectivity assay, along with NHGcapNM.  These mutants included: 
I2L, N5D, I6T, M10I, M10L, Q13H, A14S, I15V, N21S, S33C, Q50H, N57S, 
M68L, L69I, E75D, V83M, H87Q, H87R, P90T, I91T, I91V, Q95L, M96I, M96T, 
E98D, R100S, N121I, R132G, S146C, T148I, S149C, S149G, I150V, L151I, 
I153T, Y164F, R167Q, A177S, M185I, E187V, L190M, T200S, A204G, G208E, 
A209V, L211I and T216A, and were used to transfect 293T cells in 24 well plates 
as previously described.  Supernatants were harvested 48 hours later, filtered, 
and titrated onto doxycycline treated MT-4 cells encoding HsMx2, MacMx2, 
AGMMx2, OvMx2 or CanMx2, in addition to MT-4 HsMx2 cells that had not been 
doxycycline treated (as control).  At 16 hours post-infection, infected cultures 
were treated with dextran sulfate, so as to limit infection to a single cycle.  Finally, 
at 48 hours post-infection, all cells were fixed and subjected to flow cytometry, 
such that infectious titers could be calculated by counting GFP+ cells.   
 Infections of primary cells necessitated different conditions.  For the single 
cycle infections of CD4+ T cells, 1 x 106 cells were inoculated using virus 
generated from 293T cells, as described above, for the 11 rarely occurring ‘fit’ CA 
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mutants described in Figure 22C, the WT virus, and 4 randomly selected 
frequently occurring ‘fit’ CA mutants from Figure 22B (H87Q, I91V, E98D, T200S) 
at an MOI of ~5, and were fixed in 4% PFA 36 hours later and subjected to FACS 
analysis.  For infection of macrophages, vesicular stomatitis virus (VSV)-
pseudotyped virus was generated in 293T cells for the same 15 mutants plus WT 
virus, under transfection conditions in 24 well plates the same as previously 
described, but with the addition of 50 ng of VSV-G.  Macrophages were infected 
at an MOI of ~4 and fixed for FACS analysis 72 hours later.  For spreading 
infection assays in PBMC, 1 x 106 cells were infected at an MOI of 0.1, and cells 
were fixed at the time points shown in Figure 23C and then analyzed by flow 
cytometry.  The MOIs used for primary cells were reference values derived from 
titrations on MT-4 cells. 
Western blotting 
Both virions, which were initially pelleted through 20% sucrose by 
centrifugation (for 2 hours at 14000 rpm at 4°C), and cell lysates were 
resuspended in SDS sample buffer and separated by electrophoresis on NuPage 
4-12% Bis-Tris Gels (Novex).  Proteins were then blotted onto nitrocellulose 
membranes.  For the CA mutant experiments, blots were probed with either a 
primary anti-HIV p24 capsid antibody (183-H12-5C) or a primary anti-HIV MA p17 
antibody (VU47 Rabbit anti-p17 [210]) and then probed with goat anti-
mouse/anti-rabbit IRDye® 800CW secondary antibody (LI-COR Biosciences).  
For the IN mutant characterizations, blots were probed with either primary anti-
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HIV p24 capsid antibody (183-H12-5C), primary anti-HIV INT-4 antibody ([211], 
gift of Malim lab), or primary anti-clathrin heavy chain antibody (BD Biosciences, 
#610499), whilst secondary probing was done using a goat anti-mouse antibody 
(Thermo Scientific).  A LI-COR Odyssey scanner was used to detect and quantify 
fluorescent signals for all Western blots.  A minimum of 3 separate Western blots 
was produced for each temperature-sensitive mutant, including those in the 
protease negative background, and representative blots are shown. 
Structure analysis 
Structural analysis of the HIV-1 capsid hexamer was done using 
MacPyMOL, with RCSB Protein Data Bank (PDB) reference 3GV2.  
Examinations using the HIV-1 intasome model were done with structure 
coordinates provided by the authors of [168], also using MacPyMOL. 
Analyses of solvent accessible surface area values for both the CA 
hexamer and the IN intasome model were done using the UCSF Chimera 
modeling system.  
Thin-section microscopy 
In order to prepare samples for thin-section electron microscopy, 293T 
cells were seeded in 6-well plates at 0.8 x 106 cells per well, in duplicate.  
Transfections were done the following day with the addition of polyethylenimine 
to 2 μg of either the WT or mutant NHGcapNM plasmids (S33C, T48A, M96T, 
Q112L, R132G, L189M, G60W, K25I, L52F or N195S) plus 0.5 μg of modified 
human tetherin previously used in our laboratory (delGI, T45I that is resistant to 
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antagonism by HIV-1 Vpu [212]) to enhance visualization of virions at the plasma 
membrane.  Immediately after addition of the transfection mixture, plates were 
kept at either 37 or 39.5°C, as indicated.  After 48 hours, the supernatant was 
removed and the cells were fixed in a solution of 2% PFA, 2% glutaraldehyde.  
One set of cells was then analyzed by FACS to compare the transfection 
efficiencies (and these ranged from 23% for WT to 32% for L189M).  The second 
set of cells were fixed with 2.5% glutaraldehyde and 1% osmium tetroxide, and 
stained with 2% aqueous uranyl acetate.  The fixed and stained cells were then 
harvested into PBS and pelleted through 1% SeaPlaque agarose (Flowgen) at 
45°C.  The agar was then set at 4°C and the cell pellets were cut into ~2 mm 
cubes, which were dehydrated through a graded alcohol series and infiltrated 
with TAAB 812 embedding resin.  Following polymerization, thin sections (120 
nm) were cut and examined in a JEOL 1200 EX II electron microscope.  For each 
sample, numbers of virus particles associated with 150 randomly selected cells 
were counted.  Thin-section EM analyses were done with the help of Dr. Frazer 
Rixon. 
Cryo-electron microscopy 
In order to isolate virions for cryo-electron microscopy, 10 cm plates of 
approximately 4 x 106 293T cells were transfected with 7 μg of the indicated 
plasmids (NHGcapNM, R18G, K30N, G60W or M215V) using polyethylenimine.  
Approximately 48 hours later, supernatant was collected and filtered, and virions 
were pelleted by centrifugation at 14000 rpm through 20% sucrose.  Pelleted 
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virions from either WT or the CA mutants were then fixed in 10 μl of 2% PFA, 
2.5% glutaraldehyde solution. 
Subsequently, fixed aliquots of 3 μl of each sample were loaded onto 
freshly glow-discharged c-flat holey carbon grids (CF-22-4C, Protochips, Inc.) 
held at 4°C and 100% humidity in a Vitrobot vitrification robot (FEI).  The grids 
were blotted for 4 seconds prior to being frozen by plunging into a bath of liquid 
nitrogen-cooled liquid ethane.  Vitrified specimens were then imaged at a low 
temperature in a JEOL 2200 FS cryo-microscope equipped with Gatan 626 cryo-
stages.  Finally, low dose (10 e/Å2), energy-filtered images (slit width, 20 eV) 
were recorded on a Gatan ultrascan 16-megapixel charge-coupled-device 
camera at a magnification of 50,000x.  Cryo-EM analyses were done with the 
help of Dr. Saskia Bakker. 
Analysis of natural CA and IN variants 
A cohort of 1,000 HIV-1 subtype B CA sequence isolates was obtained 
from the Los Alamos HIV sequence database (www.hiv.lanl.gov).  All sequences 
were sampled from distinct infections between 1980 and 2009.  In order to 
minimize risks of sampling biases, multiple sequences from known transmission 
clusters were excluded.  Sequences with frameshift mutations or stop codons 
that were likely to represent nonfunctional viruses or poor quality sequencing 
were also excluded.  Sequences were aligned using MUSCLE [213], and PERL 
scripts were used to survey the genetic variation in the resulting sequence 
alignment.  An information-theoretic measure of diversity (Shannon’s entropy) 
 
 48 
[214] was applied to quantify the amount of amino acid variation at each capsid 
position.  Analysis of the natural variation in CA was done with the help of Dr. 
Rob Gifford.   
Similar to the cohort of sequences analyzed for CA, all HIV-1 subtype B IN 
sequences from 1980 to 2013 were selected from the Los Alamos HIV sequence 
database.  Sequences with frameshifts, stop codons, or nucleotide ambiguities 
(N or IUPAC code) were excluded from the dataset prior to randomly selecting 
1000 sequences from distinct individuals and locations.  As before, IN sequences 
were aligned using MUSCLE, with the use of PERL scripts to determine the 
number of mutations at each site in the alignment.  Shannon’s entropy was used 
to measure the amino acid diversity at each position within integrase.  The 
frequency of each amino acid was determined for each variable site.  Analysis of 
HIV-1 IN variants was done with the help of Dr. Joseph Hughes. 
The hydrophobicity and molecular weight changes were also calculated for 











Chapter 1. HIV-1 CA and creation of a randomly mutagenized CA library 
1.1 Introduction to surveying the robustness of CA through random 
mutagenesis 
HIV-1 CA is under acute competing pressures to both conserve sequence 
to preserve function, and to diversify sequence to evade immune responses.  To 
evaluate how such pressures ultimately impact genetic robustness or any 
potential trade-offs with fitness in an environment with a high mutation rate, we 
utilized an unbiased mutagenesis method to generate a large library of randomly 
mutagenized CA sequences that could simulate the natural process of random 
mutation that occurs during HIV-1 replication.  Analyses of the CA mutant library 
uncovered a remarkable degree of genetic fragility in HIV-1 CA, and it is this, 
along with its basis, in vivo correlates, and functional consequences, that will be 
subsequently analyzed. 
1.2  Creation of the CA randomly mutagenized library 
 Construction of the library of random HIV-1 CA mutants was completed by a 
former postdoc in the Bieniasz lab, Sam Wilson, but was subsequently passed on 
for the work described within this thesis.  However, as the nature of its 
construction is highly relevant to the subsequent experiments and analyses 
herein, the generation will be briefly described.   
 To begin construction, a low fidelity PCR was approach was used, as 








Figure 10.  Generation and composition of the CA mutant library.  (A) Schematic illustrating 
the replication competent proviral plasmid pNHGcapNM used for this study.  The 717 bp amplicon 
in Gag flanked by NotI and MluI restriction sites includes nearly all of CA, and a few amino acids 
in MA.  This amplicon was subjected to Genemorph II mutagenesis and subsequently subcloned 
into pNHGcapNM.  The conical capsid image was taken from PDB ID: 1VUT. 
 (B) Distribution of the number of nucleotide changes found in each library clone (including 
sequences that occurred more than once). (C) Distribution of the number of amino acid changes 
in each library clone (including sequences that occurred more than once, mutations in MA, 
nonsense mutations, and frameshifts). (D) Pie chart depicting all resulting single amino acid 
changes.  SINGLE clones were those library mutants included in further experiments.  The 
remaining clones were discarded for the following reasons: STOP (mutation resulted in a stop 
codon), MA (mutation occurred in the small fragment of MA included in the amplicon), FS 
(frameshift), DUP (duplicate mutation of a clone already in the library).  Creation of the library was 






amplified using Genemorph II, an unbiased error-prone PCR system, and cloned 
using a TOPO TA cloning kit to yield a library with an estimated complexity of 1 x 
104 clones.  Subsequently, plasmid DNA was extracted from the pooled library 
and digested, so that the mutagenized CA sequences were then inserted into the 
replication competent proviral clone, pNHGcapNM, using NotI and MluI restriction 
sites.  As noted previously, pNHGcapNM (accession: JQ686832) encodes EGFP 
in place of Nef, and will hereafter be referred to as the WT or parental virus for all 
capsid mutagenesis work.   
1.3 Composition of the CA library 
 Approximately 1000 individual colonies were then picked and proviral 
plasmid DNA was extracted from individual mini-cultures.  Each mutagenized CA 
amplicon was then sequenced for every clone, and after the removal of clones 
with failed sequencing reactions or whose chromatograms indicated the 
presence of more than one template, 680 arrayed library proviral plasmids 
remained.   Evaluations of the library composition then revealed the distribution 
of all nucleotide changes (Figure 10B), missense mutations (Figure 10C), and 
nonsense or other mutations (Figure 10D).  During the initial creation of the 
library, conditions in pilot experiments were optimized to reduce the frequency of 
both non-mutated and heavily mutated sequences in the library.  As a result, the 
most common mutation in the library was a single nucleotide or amino acid 




Chapter 2. Evaluations of CA library mutant fitness 
2.1 Fitness of all library CA mutants 
 To determine the genetic robustness of CA, we examined the ability of the 
680 CA library mutants to replicate.  Replicative fitness was analyzed using a 
spreading replication assay in which MT-4 cells were challenged with a small 
volume of virus-containing supernatant harvested from WT or CA mutant 
transfected 293T cells (equivalent to an MOI of ~0.01 for the WT virus).  After 
approximately 80 hours, and multiple rounds of the virus replication cycle, the 
experiment was concluded once the WT virus had infected more than 50% of 
cells.  Each CA mutant’s replicative fitness was then expressed as the number of 
cells that were infected (EGFP-positive), as a percentage of the number of cells 
infected by the WT virus (Figure 11A, B).  These viability screens were 
conducted at two temperatures, 35°C (Figure 11A) and 39.5°C (Figure 11B) in 
order to permit isolation of temperature-sensitive CA mutants that could facilitate 
further characterization of the replication defects associated with CA mutations 
(see below). 
 Not surprisingly, nearly all of the viral clones with WT CA sequence, or 
containing silent mutations, replicated similarly to that of the WT pNHGcapNM 
construct.  This suggested that there was a low incidence with which defective 
viruses were generated by cloning artifacts or silent mutations (Figure 11A, B).  
More importantly, these analyses of CA library replicative fitness demonstrated 






Figure 11. Fitness effects of all CA library mutants. (A) Viability of all CA mutant clones at 
35°C (excluding nonsense, frameshift, duplicate and MA mutations), indicating how the number of 
amino acid substitutions in CA affects fitness.  Replication shown is the fraction of infected MT-4 
cells (GFP+), as a percentage of the fraction infected by WT virus after a spreading replication 
assay. (B) Viability of all CA mutant clones at 39.5°C, as in (A). (C) Distribution of mutational 
fitness effects (DMFE) for all single amino acid CA substitution mutants at 35°C. (D) DMFE for all 
of the single amino acid substitution mutants at 39.5°C. Data shown in (A) and (B) was measured 
by Sam Wilson. 
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viable is arbitrarily set at 2% of WT virus replicative fitness, only 35% of the 135 
clones with single amino acid substitutions were viable at 35°C, and even fewer, 
28%, were viable at 39.5°C.  Given that the requirements for replication in an 
infected individual may be more stringent than in highly permissive MT-4 cells, 
these figures may even overestimate the proportion of mutants that are viable in 
vivo.  To this end, 2% of WT virus fitness is a rather generous cut-off to earn the 
designation of ‘viable’.  Increases in the number of amino acid substitutions 
yielded even further reductions in viability; just 6% of the 125 clones with two 
random amino acid substitutions were viable at 35°C, and this figure was only 3% 
at 39.5°C.  Accordingly, just 1 of 73 clones with 3 random amino acid 
substitutions was viable, and none of the clones with either four or five random 
substitutions could replicate at all. 
 It should be noted that the work involved in screening the entire CA library 
for viability at 35°C and 39.5°C was done by Sam Wilson.  However, his 
involvement in the work ended at this point, and all further experiments described 
herein were done independently, with the exception of some bioinformatics and 
electron microscopic analyses requiring specialist assistance. 
2.2 Fitness of single residue CA mutants 
 To better characterize the contributions of discrete residues to the genetic 
fragility of HIV-1 CA, we next focused our attention on the subset of mutants with 
unique single amino acid substitutions.  These single mutants covered 102 (44%) 
of the 231 residues in CA, and there were 33 CA residues for which there was 
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more than one unique mutation.  To evaluate robustness in more natural 
conditions, two additional infectivity assays were performed at 37°C, utilizing only 
the single residue mutants.  In the first MT-4 spreading replication assay, just 40 
mutant viruses (30%) exhibited at least 2% of parental virus fitness.  These viable 
mutants, and their corresponding fitness values can be found in Table 1, while 
the longer list of the 95 mutants (70%) with less than 2% of WT fitness in the 
spreading infectivity assay can be found in Table 2.  In the second assay, single 
cycle infectivity was measured by transfecting 293T cells with WT or CA mutant 
proviral plasmids and measuring infectivity using a larger dose of virus 
(equivalent to an MOI ~ 1 for the WT clone), and treating the MT-4 cells with 
dextran sulfate 16 h post-infection, in order to limit replication to a single cycle.  
Fitness in the replicative (spreading) versus the single cycle infectivity assay was 
generally similar (Table 1), although most mutant viruses had slightly higher 
fitness in the single cycle assay than in the spreading assay.  This phenomenon 
may be a product of the effect of transfection in the single cycle assay, in which 
overexpression of viral proteins could mask any defects, as opposed to the 
spreading infection assay in which lower gene expression levels may better 
approximate those found in the natural environment.  Alternatively, the multiple 
rounds of replication permitted in the spreading assay may enhance the effect of 
any defects in the single cycle assay. 
 Interestingly, the majority of the viable CA mutants still displayed 
attenuated infectivity, as a remarkable 89% of single amino acid substitutions  
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a Infectivity assay in which MT-4 cells were inoculated with supernatant from 293T cells (equivalent to 
MOI = 1 for WT virus) that had been transfected with single residue CA mutant proviral plasmids. 
Dextran sulfate was added 16h after infection to limit replication to a single cycle. Values are reported 
as the percentage of the number of infected cells (GFP+) obtained with the WT virus. 
b Fitness measurement in which MT-4 cells were inoculated with supernatant from 293T cells 
(equivalent to MOI = 0.01 for WT virus) that had been transfected with single residue CA mutant 
proviral plasmids. Multiple cycles of replication were allowed over a 72-80 hr time period. Values are 
reported as the percentage of the number of infected cells (GFP+) obtained with the WT virus. 
* Abbreviation for cyclophilin binding loop. 
Mutants were considered viable or infectious if they maintained 1/50 (or 2%) of WT infectivity in the 





Location in CA 
Single cycle 
infectivity 
(% of WT)a 
Spreading 
infectivity 
(% of WT)b 
I2L β-strand 90 65.6 
N5D β-strand 20 5.2 
I6T β-strand 52 56.9 
M10I β-strand 19 2.9 
M10L β-strand 73.7 27.0 
M10V β-strand 10.6 16.2 
Q13H β-strand 27.4 5.8 
A14S Loop 77.1 80.7 
A14T Loop 97.6 86.6 
I15V Loop 32.3 13.6 
N21S Helix 1 55.9 46.6 
S33C Loop 40.2 47.8 
Q50H Helix 3 19.6 3.1 
E75D Helix 4 40.8 22.1 
V83M Helix 4 75.3 64.8 
H87Q Cyclophilin b.l.* 120.3 92.0 
H87R Cyclophilin b.l. 27.5 2.5 
I91T Cyclophilin b.l. 85.2 76.9 
I91V Cyclophilin b.l. 100.0 82.8 
M96I Loop 120.3 92.0 
E98D Loop 101.0 63.4 
R100S Loop 53.9 42.5 
S146C Loop 43.7 34.0 
T148I Loop 65.8 37.3 
S149C Loop 64.8 73.7 
S149G Loop 70.9 30.3 
I150V Loop 18.6 3.1 
I153T Loop 21.2 4.7 
Y164F Helix 8 64.4 30.6 
R167Q Helix 8 11.1 5.9 
A177S Loop 99.4 37.3 
M185I Helix 9 24.2 2.5 
E187V Helix 9 59.7 47.4 
L190M Loop 38.0 32.6 
T200S Helix 10 104.2 90.4 
A204G Helix 10 77.4 89.0 
G208E Loop 15.1 3.8 
A209T Loop 108.3 94.3 
A209V Loop 72.4 84.3 
T216A Helix 11 72.4 37.5 
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I2T β-strand   E113V Helix 6 
H12R β-strand   I115K Helix 6 
Q13R β-strand   I115L Helix 6 
S16P Loop  I115T Helix 6 
R18G Helix 1  M118L Helix 6 
N21Y Helix 1  M118V Helix 6 
K25I Helix 1  H120P Loop 
V26E Helix 1  N121I Loop 
K30E Loop  I124N Loop 
K30N Loop  V126A Helix 7 
F32L Loop  I129M Helix 7 
F32S Loop  I129T Helix 7 
S33I Loop  Y130C Helix 7 
P34S Helix 2  Y130H Helix 7 
V36A Helix 2  R132G Helix 7 
M39T Helix 2  G137E Helix 7 
M39V Helix 2  L138I Helix 7 
F40L Helix 2  M144V Helix 7 
F40Y Helix 2  L151I Loop 
L43I Helix 2  L151Q Loop 
G46R Loop  I153M Loop 
P49L Helix 3  E159V Loop 
L52F Helix 3  F161C Helix 8 
N57S Helix 3  D163G Helix 8 
V59A Loop  V165A Helix 8 
V59M Loop  F168S Helix 8 
G60W Loop  R173I Helix 8 
Q63R Helix 4  A174G Loop 
A65V Helix 4  K182Q Helix 9 
M66I Helix 4  W184L Helix 9 
M66V Helix 4  W184R Helix 9 
M68L Helix 4  T186A Helix 9 
M68T Helix 4  L190S Loop 
L69I Helix 4  A194V Loop 
I73N Helix 4  N195S Loop 
A77D Helix 4  I201N Helix 10 
W80R Helix 4  L211I Helix 11 
P90T Cyclophilin b.l.  E212D Helix 11 
Q95L Loop  M214L Helix 11 
Q95R Loop  M215V Helix 11 
M96T Loop  A217V Helix 11 
P99A Loop  Q219P Loop 
P99L Loop  G220V Loop 
R100W Loop  V221A Loop 
S102R Helix 5  K227I Loop 
A105G Helix 5  K227N Loop 
T110I Loop  K227R Loop 
L111F Helix 6    
 
Mutants were considered nonviable if they exhibited <2% of WT fitness in the spreading fitness 




caused a greater than 2-fold reduction in infectious virion yield.  This observation, 
in conjunction with the lack of mutants with replicative fitness greater than WT, 
indicates that it may be difficult to improve upon the fitness of the parental CA, 
which may already be near a fitness peak.  Another way of analyzing the overall 
robustness of the single residue mutants is to examine the distributions of 
mutational fitness effects (DMFE).  Previous work analyzing panels of RNA virus 
single amino acid mutants have presented DMFE values that were bimodal in 
nature, with substitutions typically resulting in either minor reductions in fitness or 
lethality [86,87,93,94,95,96].  While this phenomenon was also true to some 
extent for HIV-1 CA (Figure 11C at 35°C, Figure 11D at 39.5°C, Figure 12 at 
37°C), the proportion of nonviable CA mutants was significantly larger than has 
previously been reported [86,87,93,94,95,96], so that the proportion of viable CA 
mutants was also significantly smaller than earlier reports, and the occurrence of 
mutants with only minor fitness defects was also greatly reduced in the case of 
HIV-1 CA (Figure 11C, D, Figure 12).  
 Assessments of Tables 1 and 2 reveal that different mutations at the same 
residue in CA, such as I2, can sometimes result in highly variable fitness effects, 
suggesting that the type of residue change is not entirely insignificant.  However, 
analyses of the mutant residues’ changes in hydrophobicity or molecular weight 
for the entirety of the single residue mutant CA library did not reveal any general 
associations with replicative fitness (Figure 13A, B).  While some polar residues 









Figure 12. Fitness effects of single residue mutations in the CA mutant library.  Distribution 
of mutational fitness effects (DMFE) for all single amino acid CA substitution mutants, using 




























































Figure 13. Changes in hydrophobicity or molecular weight are not primary determinants of 
fitness.  (A) Evaluations of the effect of the type of residue change for all library mutations on 
fitness (in a spreading replication assay).  Letters indicate changes from the initial type of residue 
to the mutated residue type, as indicated in the legend.  Analyses of disparities between 
conservative changes (i.e., polar (P) to polar (P)) and nonconservative changes (i.e., polar to 
nonpolar (NP)) were performed for all scenarios, and all significant differences are indicated. (B) 
Evaluations of the effect of the size of mutant residues’ molecular weight change on fitness (in a 
spreading replication assay).  Analyses between residue substitutions in which there was no 
change in molecular weight and those with either increases or decreases in molecular weight 

































































































































PB = polar, basic




patterns related to hydrophobicity changes suggests that types of residues 
changes are not significant determinants of CA fitness.  Moreover, inspection of 
Tables 1 and 2 reveals that the position within CA was a far greater determinant 
of a mutation’s fitness effect.  Of the 231 residues in CA, 56.3% lie within CA’s 11 
helices, 5.6% are in the N-terminal β-strand, 3.9% are in the cyclophilin A binding 
loop, and the remaining 34.2% are in interhelical loops.  Together, these figures 
provide a context in which it is possible to summarize mutant fitness by region, in 
order to indicate areas of particular genetic fragility in CA (Table 3, Figure 14).  
Notably, there were distinct regions of relative robustness within CA, as 70-100% 
of mutants retained some viability within the N-terminal β-strand, the cyclophilin 
binding loop, and the interdomain linker region.  In contrast, just 16% of mutants 
in helices maintained viability, and an intermediate 39% of mutants retained 
viability within the interhelical loops.  More strikingly, all 25 mutations in helices 2, 
5, 6, and 7 resulted in nonviability, suggesting these N-terminal helices are 
particularly fragile.  When these results are graphically represented such that the 
fitness of each mutant is plotted against its position in the linear CA sequence 
(Figure 14), it is even more apparent that regions of mutational fragility are non-
uniformly distributed in CA, with mutations in NTD helices the most likely to result 
in inactivation (Figure 14). 
2.3 Locations of library mutations on the CA hexamer structure 
 When CA mutant fitness is displayed within the context of a capsid 





Table 3.  Summary of CA mutant viability by CA region 
 





β-strand 7 3 70 
Helix 1 1 4 20 
Helix 2 0 7 0 
Helix 3 1 3 25 
Helix 4 2 10 17 
Cyclophilin b.l. 4 1 80 
Helix 5 0 2 0 
Helix 6 0 7 0 
Helix 7 0 9 0 
Helix 8 2 5 29 
Helix 9 2 4 33 
Helix 10 2 1 67 
Helix 11 1 5 17 
MHR 3 6 33 
Interdomain linker 5 0 100 
Helices (all) 11 57 16 
Loops (all) 22 35 39 
NTD 27 68 28 























Figure 14. Linear distribution of fitness effects of single residue CA mutations.  Plot of 
fitness values for CA mutants in which the location of the mutation is arranged on the X-axis from 
left (N-terminal residue) to right (C-terminal residue) with their corresponding fitness values (as 

















































Figure 15. Mapping of CA fitness to the CA hexamer structure. (A, B) Location of single 
amino acid mutant residues on an X-ray crystal structure of the CA hexamer (PDB: 3GV2). 
Images on the left show the hexamer as viewed from the exterior of the intact capsid, while center 
images show the hexamer as viewed from within the plane of the capsid lattice, and rightmost 
images show the hexamer as viewed from the interior of the intact conical capsid.  Green 
residues, shown in (A), are those that had greater than 2% of WT fitness in a spreading 
replication assay when mutated (viable mutants).  Red residues, shown in (B), are those that had 
less than 2% of WT fitness in a spreading replication assay when mutated (nonviable mutants). 
For residues with more than one mutation, the most fragile result was plotted. (C) Comparison of 
fitness and residue surface exposure, as determined by the solvent accessible surface area 
(calculated using UCSF Chimera with PDB 3GV2).  Mutated residues were grouped as having 
either a solvent accessible surface area  <50Å2 or a solvent accessible surface area >50Å2.  
Fitness is plotted in accordance with the grouped residue.  Significance was determined using 






















viable mutants (in green, Figure 15A) appear more likely to occur at surface 
exposed residues.  Conversely, the mutations shown in the interior regions of the 
CA structure almost always resulted in nonviable mutants (displayed in red, 
Figure 15B).  This observation is particularly evident when the CA hexamer is 
viewed from a point of view from the interior of the assembled capsid (Figure 
15B, rightmost images), and further emphasizes the impression of an inner CA 
‘core’ structure, composed of helices that are particularly intolerant to mutation. 
 Such findings are further confirmed quantitatively by analysis of the 
solvent accessible surface area values for individual mutated residues (Figure 
15C).  Specifically, the mutated residues with solvent accessible surface area 
values less than 50 Å2 (a suitable cutoff for surface exposure based on previous 
mutagenesis studies [215]) had significantly larger fitness defects (p=0.003).  
These more buried mutant viruses (with solvent accessible surface areas less 
than 50 Å2) displayed a mean fitness value of only 2.8% of WT (Figure 15C).  
However, viruses harboring mutations in more surface exposed residue locations 
(with solvent accessible surface areas greater than 50 Å2) displayed a much 
larger mean fitness value, at 18% of WT (Figure 15C). 
 
Chapter 3. Biological basis for the genetic fragility of HIV-1 CA 
3.1 Analysis of conditionally nonviable (temperature-sensitive) CA mutants 
 As has been already mentioned, CA performs numerous critical functions 
during HIV-1 replication, including its roles mediating the assembly of immature 
 
 66 
virions (in the context of the Gag precursor) and the formation of a mature conical 
capsid.  In addition, the optimal stability of capsid is thought to be important to the 
uncoating step of the HIV-1 cycle in newly infected cells, and CA is also critically 
involved in the import of the viral genome into an infected cell’s nucleus.  As it 
was unclear which, if any, of these functions was responsible for the extreme 
genetic fragility of CA, a number of assays were performed to elucidate the 
nature of replication defects in both constitutively and conditionally nonviable CA 
mutants. 
 During analysis of the initial viability screens performed on the entire CA 
library (Figure 11 A, B), we observed that a small subset of CA mutants were 
viable at a permissive temperature of 35°C, but had severely reduced fitness at a 
nonpermissive temperature of 39.5°C, whereas most CA mutants were 
approximately equally fit or unfit at both temperatures.  This subset of 
temperature-sensitive (ts) conditionally nonviable mutants included both single 
and double residue mutants, and so CA mutants encoding only single amino acid 
substitutions in isolation were generated.  In total, eleven single amino acid CA 
mutants with large ts replication phenotypes were selected for examination. 
 Since the initial viability screen in which we identified the presence of ts 
mutants had measured replicative fitness over multiple rounds of replication, it 
did not determine which specific step in the viral life cycle was impaired in the 
constitutively or conditionally nonviable mutants.  Thus, it seemed prudent to 
determine the single cycle infectivity of the ts CA mutants, utilizing virions 
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generated at 35°C, 37°C, or 39.5°C in 293T cells, which were then used to infect 
MT-4 cells at 35°C, 37°C, or 39.5°C (Figure 16A, B).  As Figure 16A 
demonstrates, the parental control, pNHGcapNM, has a consistent viral titer 
regardless of the temperature of production or infection.  It is also apparent that 
most of the ts CA mutants had similar, or modestly reduced, infectivity as 
compared to the parental virus when virion production and infection were done at 
the permissive temperature (35°C) (Figure 16A).  Strikingly however, when 
restrictive temperatures were applied during virion production, single cycle 
replication of all the ts mutants was inhibited at least 50 to 1000-fold (Figure 16A, 
B).  Conversely, when restrictive temperatures were applied only during infection, 
and not production, the single cycle replication of all of the ts mutants was 
completely unaffected.  These results demonstrate that the defects associated 
with conditionally nonviable ts CA mutants occurred exclusively and irreversibly, 
during, or immediately after, particle production, and not during earlier steps of 
the viral life cycle (such as uncoating or nuclear import). 
 Subsequent examination of Gag expression and processing by the ts CA 
mutants and WT virus showed similar levels of cell-associated Gag precursor 
Pr55 and capsid p24 were present regardless of the temperature of production 
(Figure 17A).  Alternatively, analysis of extracellular virion-associated p24 
showed 57% to 88% reductions in p24 levels at the restrictive temperature for the 
ts CA mutants only (Figure 17A).  Since it was possible that the ts CA mutants 






Figure 16. Conditionally viable (ts) CA mutants display defects only when assembled at a 
nonpermissive temperature.  (A) Measurements of infectious virion titers from 293T cells 
transfected with either the parental or ts single residue mutant proviral plasmids, and placed at 
either 35°C (filled circles), 37°C (filled squares), or 39.5°C (filled triangles) for production of 
virions, as the distinct plot lines indicate.  Titers of viruses from resulting supernatants from each 
mutant were measured in MT-4 cells at 35, 37, or 39.5°C, as displayed on the x-axis.  Dextran 
sulfate was added 16h post-infection to restrict replication to a single cycle. (B) As in (A), but here 
the temperature of virus production is indicated on the x-axis and inoculations were done in MT-4 
cells at 37°C only. 
Parental




























































































































































































































Figure 17. All conditional (ts) CA mutants display reductions in extracellular particle yield 
at the nonpermissive temperature.  (A) Western blot analysis, using an anti-CA antibody, of 
cell lysates and virions generated in 293T cells transfected with the indicated ts CA mutant or WT 
proviral plasmid.  For each mutant, two lanes are shown: on the left is the sample from cells 
incubated at 35°C following transfection (Lo, permissive), and on the right is the sample from cells 
incubated at 39.5°C following transfection (Hi, nonpermissive).  The numbers shown below each 
lane specify the fluorescence intensities (LI-COR) associated with the CA protein pelleted from 
virion-containing supernatant.  (B) Western blot analysis, as in (A), but instead utilizing an anti-
HIV-1-MA antibody (p17) to show expression in cell lysates and virions for the same mutant 
panel.  The numbers shown below each lane specify the fluorescence intensities (LI-COR) 




analysis of Gag expression, processing, and particle production by the ts mutants 
was also done using an anti-p17 matrix (MA) antibody (Figure 17B).  Again we 
observed uniform levels of p17 in cell lysates regardless of the temperature of 
production.  However, there were large reductions in p17 extracellular particulate 
expression for the ts CA mutants at the nonpermissive temperature, as the 2.4-
25 fold decreases in p17 indicated that particle production was decreased by 59-
96%.   
 While the 2.3 to 25-fold reductions in particle production observed for the 
ts CA mutants is smaller than the corresponding 50 to 1000-fold reductions in 
infectious virion yield, it should be noted that the majority (57 to 96%) of the 
reduction in infectivity must be due to an inability for these mutants to efficiently 
generate particles.  However, these results do also suggest that since the block 
in the generation of particles was not absolute, there was also some degree of 
generation of poorly infectious particles, such that attenuation of particle 
production by ts CA mutants at the nonpermissive temperature varied, rather 
than being entirely defective.  Ultimately, the inability of the ts CA mutants to 
efficiently generate particles at the restrictive temperature is in alignment with the 
observation that it is the temperature during particle production, not infection, that 
determined the phenotype we observed for all of the ts mutants, and that all of 




 Interestingly, inspection of both anti-CA and anti-MA ts mutant blots 
revealed a specific irregularity in Gag processing.   As is typical, the parental 
virus generated a single ~41 kDa band that was recognized by both anti-CA and 
anti-MA antibodies at permissive and restrictive temperatures (presumably the 
p41 MA-CA-p2 processing intermediate, Figure 17A, B).  The same was also true 
for the ts CA mutants at the permissive temperature, however, at the restrictive 
temperature, one to two additional protein species appeared at a similar, but not 
identical mobility, to p41.  Therefore, for all ts CA mutants, attenuated particle 
production was accompanied by a disruption in Gag processing, which may be 
further linked to the overall defects in particle yield and infectiousness.  
Remarkably, for all eleven ts CA mutants, elimination of the activity of the viral 
protease also eliminated the temperature-dependent reduction in particle yield 
(Figure 18).  This permits the conclusion that the capsid mutations that instigate 
temperature-sensitive attenuations of particle production do not do so prior to 
activation of the viral protease.  Combining this observation with the observation 
that the temperature of inoculation did not impact infectivity, permits the 
conclusion that all eleven conditionally nonviable CA mutants have defects that 
are manifested during, and not before or after, virion morphogenesis.  
3.2 Analysis of constitutively nonviable CA mutants 
 Investigation of the eleven conditionally nonviable CA mutants suggested 
that the fragility of HIV-1 CA arises from requirements imposed during production 









Figure 18. The conditional (ts) CA mutant reduction in particle yield is protease 
dependent.  Western blot analysis of the cell lysates and virions generated by 293T cells 
transfected with the ts CA mutants (and WT) expressed in a protease-defective proviral plasmid 
(Pr-). Numbers below each lane indicate the fluorescence intensities (LI-COR) associated with 











conceivable that the examination of conditionally, rather than constitutively, 
nonviable mutants could have biased this conclusion.  To remedy this, a larger 
set of 81 constitutively nonviable mutants was examined for their ability to 
generate extracellular particles by western blot. (Figure 19A). 
 A striking number (74%) of constitutively nonviable mutants displayed 
greater than 5-fold reductions in extracellular particle yields.  Still, a minority 
(20%) of the lethal mutations did not significantly impact the magnitude of particle 
production (less than 2-fold reductions in total particle yield), but instead resulted 
in the efficient generation of noninfectious particles (Figure 19A).  The other 6% 
of the constitutively nonviable mutants had an intermediate phenotype in which 
particle reduction was reduced 2 to 5-fold.  Occasionally, such as at residues 
K30, M39, and I115, a change to one amino acid resulted in efficient generation 
of noninfectious particles, while a change to a different amino acid caused a large 
reduction in particle yield.  However, there again appeared to be no trends in 
amino acid property that could definitively determine what might cause mutants 
to efficiently generate noninfectious particles as opposed to causing attenuated 
particle formation (Figure 13).  In alignment with the hexamer mapping 
distribution of the inactivating CA mutants, constitutively nonviable mutants that 
yielded WT levels of noninfectious particles also mapped to the inner core of the 
hexamer (compare Figures 19B and 15B).  Furthermore, we also observed that 
many of the constitutively nonviable CA mutants displayed evidence of disrupted 





Figure 19. Most constitutively nonviable CA mutants display attenuated particle formation. 
(A) Western blots showing cell lysates and virions from nonviable mutants (those with <2% of WT 
fitness in a spreading replication assay) probed with an anti-CA antibody.  It should be noted that 
multiple individual substitutions between residues 159 and 168 yielded diminished signal when 
the monoclonal anti-CA antibody was used (derived from hybridoma 183-H12-5C).  To this end, 
CA carrying a R167Q mutation is infectious, but is not recognized by this antibody (unpublished 
observation) suggesting that the epitope of the antibody lies in this region.  Therefore, it is likely 
that the E159V substitution, shown in A, may also disrupt antigen recognition, accounting for the 
lack of signal in this lane. (B) Locations of mutations in the CA hexamer that are constitutively 
nonviable, but express near WT levels of particle formation.  The image on the left shows the 
hexamer as viewed from the exterior of the intact conical capsid, the center image shows the 
hexamer as viewed from within the plane of capsid lattice, and the rightmost image shows the 





protein species, very similar to those present in conditionally nonviable mutants 
at the restrictive temperature (Figures 19A, 17A, and 17B).  Taken collectively, 
these data reinforce the conclusion that the primary determinant of mutational 
fragility in HIV-1 CA is the requirement to mediate the efficient and accurate 
assembly of particles. 
3.3 Evaluations of fragility by electron microscopy 
 To further investigate the nature of the defects in conditionally and 
constitutively nonviable CA mutants, we utilized electron microscopy (EM) to both 
quantify and visualize particle morphogenesis.  First, to examine the ts CA 
mutants, 293T cells were transfected at 39.5°C with either the parental proviral 
plasmid or one of six randomly selected ts CA mutant proviral plasmids, plus a 
plasmid expressing a modified Vpu-resistant human tetherin (delGI, T45I) [212], 
in order to maintain virions at the plasma membrane to facilitate visualization.  
Examination of 150 cells for each ts CA mutant revealed that these mutants 
generate drastically fewer particles at the restrictive temperature (Figure 20A, 
shaded bars), with reductions ranging from 4 to 221-fold (75 to 99.5% fewer 
particles).  Visualization of the particles revealed that some of the particles 
generated by the ts CA mutants seemed morphologically normal, but there also 
appeared to be a higher fraction of irregular particles and budding structures as 
compared to the parental virus (Figure 20B).  Overall, the smaller number of 






Figure 20. Electron microscopic analysis of particle formation by conditionally nonviable 
CA mutants. (A) Analysis of thin-section EM images showing the total number of particles 
produced by either parental virus or ts CA mutants at the restrictive temperature (39.5°C) in 293T 
cells.  Circles represent the number of particles produced by individual cells (n=150 cells for each 
sample), while the shaded bars indicate the total number of particles counted in the 150 cells. (B) 
Representative images of the thin-section EM samples analyzed in (A).  Scale bars apply to all 




































































draw definitive conclusions about the morphological characteristics of the 
particles that were produced. 
 Thin-section EM analyses were also conducted on 293T cells transfected 
with three randomly selected constitutively nonviable mutants (K25I, L52F, and 
N195S) that had shown significantly reduced extracellular particle yields (Figure 
21A, B).  As before, this was done in the presence of tetherin (delGI, T45I) to 
enable inspection and quantification of viral particles.  These analyses revealed 
large reductions in particle yields similar to those that characterized the 
conditional ts CA mutants.  In this case, particle yields were reduced ~6 to 28-
fold (82 to 96% fewer particles) as compared to the parental virus.  For mutants 
K25I and L52F, the small number of particles generated appeared to have 
morphologies similar to the parental virus, but the budding structures produced 
by mutant N195S were obviously abnormal (Figure 21A, B).  Intriguingly, irregular 
morphologies very similar to those observed for N195S were previously reported 
for mutations at a nearby CA residue, D197 [155]. 
 So as to provide an additional control for these experiments, we also 
investigated particle production by EM for a constitutively nonviable mutant 
(G60W) that displayed high levels of noninfectious particulate p24 in western blot 
analyses (Figure 21A, B).  This mutant actually produced even more numerous 
particles than the parental virus.  Together, the data obtained from the EM 
analyses of particle formation broadly supported the estimates of particle 






Figure 21. Electron microscopic analysis of particle formation by constitutively nonviable 
CA mutants. (A) Analysis of thin-section EM images showing the total number of particles 
produced by either parental or constitutively nonviable CA mutants in 293T cells at 37°C.  Circles 
represent the number of particles produced by individual cells (n=150 cells for each sample), 
while the shaded bars indicate the total number of particles counted in the 150 cells. (B) 
Representative images of the thin-section EM samples shown in (A) for WT and samples with 
reduced particle yields. Scale bars shown apply to all images. (C) Representative thin-section EM 
images for three constitutively nonviable CA mutants that had high yields of noninfectious 
particles. (D) Cryo-EM images of purified virions from either parental virus or four constitutively 





































and further emphasizes the notion that most randomly introduced CA mutations 
cause substantial attenuation, but not complete elimination, of particle formation. 
 Since a minority (20%) of constitutively nonviable mutants resulted in 
normal levels of extracellular particles that were noninfectious, we randomly 
selected an additional three such mutants (R18G, G60W, and M215V) for thin-
section EM examination (Figure 21C).  None of these mutants displayed particle 
morphologies that notably differed from particles produced by the parental virus.  
Moreover, inspection of cell free virions produced by these same mutants, plus 
one additional nonviable mutant (K30N) was also done by cryo-electron 
microscopy (Figure 21D).  Particle morphologies for these mutants again 
appeared similar to the WT, perhaps with the exception of G60W, which 
displayed cores that were more difficult to discern.  
 
Chapter 4. Analyses of CA library mutations in natural HIV-1 subtype B 
populations 
4.1 Occurrence of library CA mutations in an in vivo cohort  
The in vitro measurements of HIV-1 CA mutant fitness suggested that the 
high degree of fragility could place tight constraints on the sequences of CA that 
are found in natural populations.  Consequently, we obtained a set of 1,000 CA 
sequences isolated from HIV-1 subtype B infected individuals, so as to compare 
the fitness of our individual library single amino acid HIV-1 CA mutants with the 
frequency of their occurrence in vivo.  From a plot in which in vitro replicative 
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fitness of CA mutations is measured against the frequency with which the 
mutations occur in natural populations (Figure 22A), it is clear that only mutants 
that exhibited at least 40% of parental virus fitness in our spreading infectivity 
assays occurred at a frequency greater than 1% in natural populations.  
Curiously, however, there was a distinct bimodal distribution regarding the in vivo 
occurrence of the nineteen random mutants that exhibited >40% parental virus 
fitness.   While some of these fit mutants occurred relatively frequently (i.e. in 
>3% of natural sequences, Figure 22B), others occurred extremely rarely or 
never (<0.3% of natural sequences, Figure 22C).  This indicates that there exists 
a subset of mutations that incur little or no obvious fitness cost, but are still 
largely absent from HIV-1 subtype B natural populations.  Consistent with their 
lack of effect on fitness, these seemingly innocuous, but rare, mutant residues 
occurred preferentially on the outer surfaces of the hexamer, and avoided the 
inner hexamer core (Figure 22D). 
4.2 Examination of ‘rare’ and ‘frequent’ mutations in primary cells 
 The observation that more than half of the random CA mutants that were 
fit in vitro occurred either extremely rarely or never in vivo was surprising given 
the expectation that HIV-1 will take advantage of all available sequence space 
that does not eliminate fitness.  Data from these analyses suggested that some 
mutations may be selected against in vivo in a manner not initially revealed by 






Figure 22. Analysis of CA library mutations in natural HIV-1 subtype B populations.  (A) 
Plot indicating the frequency with which the library mutations occur in 1000 natural HIV-1 subtype 
B CA sequences (Y-axis) versus the fitness of the same mutations in a spreading replication 
assay (X-axis).  The vertical dashed line shows 40% of WT fitness, below which mutants 
occurred rarely in nature, while the horizontal dashed line indicates 3% frequency, above which 
mutants were considered to occur frequently in vivo.  Mutants with less than 0.01% WT fitness 
and that were not observed in nature would appear at the origin of the graph, and are not shown. 
(B) Library mutants that occurred at a frequency greater than 3% in 1000 subtype B sequences 
and their corresponding fitness values. (C) Fit library mutants that occurred rarely (less than 
0.3%) or never in 1000 subtype B isolates, and their corresponding fitness values. (D) Mapping of 
the residues, shown in (C) on the CA hexamer, where mutations resulted in minimal reductions in 
fitness (>40% of WT spreading replication), but occurred in less than 0.3% of subtype B isolates.  
The image on the left shows the hexamer as viewed from the exterior of the intact conical capsid, 
the center image shows the hexamer from within the plane of the capsid lattice, and the rightmost 
image shows the hexamer as viewed from within the interior of the intact conical capsid. 
















Mutant Frequency (%) 
Spreading 
fitness  
(% of WT) 
I2L 0 65.67 
I6T 0.1 56.88 
N21S 0.2 46.55 
S33C 0 47.82 
I91T 0.2 76.87 
R100S 0 42.51 
S149C 0.1 73.68 
E187V 0 47.39 
A204G 0 89.01 
A209T 0 94.30 
A209V 0 84.29 
!
Mutant Frequency (%) 
Spreading 
fitness  
(% of WT) 
A14S 3.2 80.69 
A14T 3.2 86.62 
V83M 3.7 64.78 
H87Q 18 92.04 
I91V 29 82.84 
M96I 9.8 92.04 
E98D 12.3 63.37 








can have cell-type dependent effects on HIV-1 infectiousness [133,134,216,217], 
so it was conceivable that the fit but ‘rare’ mutations might exhibit fitness  
defects that are manifested in primary cells, but not in permissive MT-4 cells.  To 
evaluate this possibility, replication assays were performed in multiple primary 
cell types, using 11 apparently fit mutants viruses that occurred rarely in natural 
populations (Figure 22C) and 4 randomly selected fit viruses that occurred 
frequently (Figure 22B). 
 Our analyses indicated no significant differences between the ability of 
rarely or frequently occurring fit mutations to infect peripheral blood mononuclear 
cells (PBMCs), primary CD4+ T cells, or macrophages in short term (semi-single 
cycle) infection assays (Figure 23A, B, C).  Moreover, there was no significant 
difference in the capacity of the rarely and frequently occurring mutations to 
replicate in a spreading infection assay in PBMCs (Figure 23C).  Ultimately, it 
appears that the rarity of certain apparently fit mutations in HIV-1 subtype B 
populations is not related to differences in their capacities to replicate in primary 
cells.  Instead, these findings suggest that there is some unknown selective 
pressure that permits some intrinsically fit CA variants, but not others, to persist 
in vivo. 
4.3 Correlation between fitness and variation in CA 
 To further examine the relationship between the CA mutations’ fitness in 
vitro and their occurrence in natural HIV-1 subtype B populations, analyses were 







Figure 23. ‘Rare but fit’ CA mutants are indistinguishable from frequently occurring fit 
mutants in primary cells. (A) Plot indicating the percentage of infected macrophages after 
infection with VSV-G pseudotyped WT virus (NHGcapNM, filled squares) or VSV-G pseudotyped 
fit CA mutations (>40% WT fitness) that occurred either rarely (filled circles) or frequently (filled 
triangles) in natural sequences.  Mutants are those found in Figure 22. (B) Plot indicating the 
percentage of infected stimulated CD4+ T cells, as indicated in (A) (not pseudotyped). (C) Plot 
showing spreading replication in PBMCs, as indicated by the number of GFP+ cells, after 
infection (MOI = 0.1) of stimulated peripheral blood mononuclear cells with virus from either WT 





















































































measured by Shannon entropy values) with the propensity of CA domains or 
regions to tolerate mutation.  It seemed a logical expectation that the regions that  
are more robust (Figure 14) would have higher levels of variability in natural 
populations.  Similar to what was shown in a previous analysis of the Shannon 
entropy of the N-terminal of subtype C HIV-1 CA [142], our analyses revealed 
regions of high entropy in CA (>0.4), and other regions that were more conserved 
(Figure 24A).  Clearly, there is also a degree of accord between the capacity of 
CA domains to tolerate mutation and the Shannon entropy values.  This is 
particularly evident in regions of comparatively high robustness and high entropy, 
such as the cyclophilin binding loop, residues ~5 to ~35, and residues ~175 to 
~210.  There were also regions in which especially low robustness corresponded 
with low variability in vivo, such as helices 2 and 3, and also in the major 
homology region (Figure 24A).  Nevertheless, there were also some 
discrepancies between the Shannon entropy and robustness profiles throughout 
CA.  For example, fitness measurements revealed helices 5, 6, and 7 to be highly 
genetically fragile, but the Shannon entropy values in this region were often quite 
high.  Ultimately this finding suggests that it is likely that selective pressures in 
addition to fitness act on the HIV-1 CA sequence in vivo. 
 One such selective pressure likely to impose pressure on CA is that of the 
adaptive immune system, and in particular, cytotoxic T-lymphocytes (CTLs), 
which are able to recognize peptides derived from HIV-1 CA.  Several previous 







Figure 24. Correlation between CA fitness and natural variation. (A) Plot in which the fitness 
of the library of CA mutants is overlaid with the Shannon entropy values, derived from 1000 
subtype B CA isolate sequences, for each residue in capsid.  Locations of CA residues are 
arranged on the X-axis from left (N-terminal residue) to right (C-terminal residue), and their 
corresponding replicative fitness (as % of WT in a spreading replication assay) and Shannon 
entropy values are shown on the Y-axes.  The positions of ‘protective’ CTL epitopes are indicated 
by horizontal blue lines. (B) Distribution of mutational fitness effects (DMFE), at 37°C, for all 
single amino acid CA substitution mutants that occurred either in or outside the protective 
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certain mutations in CA [142,143,144,145].  More importantly, some of these 
studies have demonstrated that immune responses to certain epitopes in CA can 
be protective, such that their presence is associated with slower disease 
progression.  Interestingly, some of the most frequently studied, and most 
protective epitopes appear to occur preferentially in regions of extreme genetic 
fragility, as can be seen for HLA-B*57-restricted epitopes KF11 (residues 30-40) 
and TW10 (residues 108-117), and the HLA-B*27-restricted epitope KK10 
(residues 131-140) (Figure 24A, Table 2).  Furthermore, a comparison of the 
DMFE values for the 41 library mutations that occurred in so-called protective 
epitopes (specifically, QW11 (residues 13-23), IW9 (residues 15-23), KF11 
(residues 30-40), TL9 (residues 48-56), EW10 (residues 71-80), TW10 (residues 
108-117), DA9 (residues 166-174), KK10 (residues 131-140)) with the 94 library 
mutations that occurred outside these epitopes indicated that the protective 
epitopes occur in regions of CA that are more genetically fragile than the rest of 
the CA sequence (Figure 24B).  Indeed, whereas the mean fitness value for 
mutations occurring outside these protective epitopes was 15.1% of WT, the 
mean fitness value for mutations within the epitopes was just 7.9% of WT.  
4.4 Summary of effects of random mutations in HIV-1 CA. 
 By utilizing the scope of the mutagenesis in these studies of CA, in which 
almost half of the amino acids in CA were individually mutated, in conjunction 
with the analyses of the frequency of these mutations in natural populations, it is 
possible to make generalized predictions about the fate of randomly introduced 
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nucleotide substitutions (Figure 25A) or amino acid substitutions (Figure 25B) in 
CA.  For cases of random nucleotide changes (Figure 25A), 22% should result in 
synonymous changes that, in most cases, will not affect fitness (Figure 11).  If 
fitness was the only negative selection pressure in vivo, then 10% of nucleotide 
substitutions would be expected to result in a nonsynonymous change that is 
sufficiently replication competent (>40% of WT fitness in vitro) to potentially 
flourish in natural populations.  However the results from Figure 22 suggest that 
only a minority of the mutations that yield variants with >40% of WT fitness in 
vitro are actually capable of thriving in vivo, and by this limitation, just 4% of all 
nucleotide substitutions would be expected to yield nonsynonymous changes that 
could flourish in a natural environment. 
 If only nonsynonymous substitutions are considered (Figure 25B), then 
87% should result in nonviable virus, with most mutations (59%) causing >5-fold 
reductions in particle formation, and a smaller portion (21%) resulting in the 
generation of particles (at at least 20% of the level of WT) that would be 
noninfectious.  Just 13% of nonsynonymous substitutions are predicted to be 
adequately replication competent (at least 40% of WT replicative fitness) to 
potentially flourish in vivo, based on intrinsic fitness measurements.  Again, 
however, only a fraction of intrinsically fit mutants were shown to persist in vivo, 
such that only 5% of all CA amino acid substitutions are actually expected to 










Figure 25. Summary of the effects of random mutations in HIV-1 CA. (A) Assessment, as 
estimated from the in vitro and in vivo data shown previously, of the likelihood of various 
outcomes for random single nucleotide substitutions (A) and random single amino acid changes 
(B).  The charts indicate changes that fall into one of the following categories: synonymous (A 
only), nonsynonymous, or nonsense (as determined computationally using the pNHGcapNM CA 
sequence). Since the only mutants frequently observed in natural populations are those with 
fitness >40% of WT in vitro, this threshold was used to consider which mutants could thrive in 
vivo (the proportion of random mutants with fitness less than 40% of WT was derived from data in 
Tables 1 and 2).  The proportion of mutants expected to thrive (nonsynonymous, viable in vitro 
and in vivo) and not to thrive (nonsynonymous, viable in vitro only) was derived from the data in 
Figure 22 showing the occurrence of library mutations in natural populations.  A red 
circumferential line indicates the fraction of random mutants expected to be nonviable in vivo.   
Fates of the remaining mutants were derived from the data shown in Figure 19 (nonsynonymous, 











Chapter 5. Additional applications of the CA mutant library 
5.1 Screen of CA library for resistance to Mx2 restriction 
 Aside from demonstrating a rather extreme intolerance to mutation, the 
randomly mutagenized CA library we have created can also be utilized in other 
screening approaches to test the relevance of capsid and its residues in 
numerous other HIV-1 functions.  Among the biological properties of capsid are 
multiple physical interactions with host cell proteins, including karyopherin β 
transportin-3 (TNPO3), nucleoporin 153 (NUP153), nucleoporin 358 
(NUP358)/RanBP2, cleavage and polyadenylation factor 6 (CPSF6), and 
cyclophilin A [128,129,130,131,132,133,218], and it seems likely further proteins 
will be added to this list.  Work from our laboratory, and others, has recently 
highlighted how Myxovirus resistance protein 2 (Mx2, sometimes referred to as 
MxB) can efficiently inhibit early steps of HIV-1 infection in vitro [136,137,138].  
While the mechanisms by which the interferon-mediated Mx2 suppresses HIV-1 
replication have not been clear, these studies have all reported HIV-1 capsid to 
be a significant determinant of Mx2 sensitivity, as a few capsid amino acid 
substitutions were able to confer either partial or complete resistance to Mx2 
activity.  These reported mutations reducing sensitivity to Mx2 were largely 
localized to the cyclophilin binding loop (at residues 88-90, 92 and 94), but also 
included one mutation, N57S, which has previously been reported to impact HIV-
1 infection of non-dividing cells [127,136,137,138]. 
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 To identify other CA residues that could confer resistance to the antiviral 
activities of Mx2, 46 of the CA library mutants that had greater than 2% of WT 
infectivity in the single cycle infectivity assay were selected and used to 
challenge MT-4 cells expressing Mx2 from various species (Figure 26A).  The 
ovine and canine variants of Mx2 displayed almost no antiviral activity against 
either WT or any of the CA mutant viruses.  In contrast, most of the CA mutants 
were inhibited by primate Mx2 species variants from human (Hs), macaque 
(Mac), and African Green Monkey (Agm) (Figure 26A).  Interestingly, however, 
seven of the CA mutants conferred significant resistance to at least one of the 
primate Mx2s (Figure 26A, B). 
 Like the previous studies of Mx2, several mutations in the cyclophilin 
binding loop were able to confer resistance to Mx2.  These included the P90T 
substitution, which had not previously been reported, and conferred total 
resistance (in Hs), as well as substitutions at newly implicated residues, H87R 
and Q95L, that conferred significant partial resistance, to varying degrees, in the 
different primates.  Identification of these two mutations, together with the 
previously established Mx2 resistant capsid mutations, suggests that the 
cyclophilin binding loop is likely an important Mx2 sensitivity determinant.   
Perhaps more interesting was the identification of the other CA mutants 
promoting Mx2 resistance.  Two mutants in the N-terminal domain conferred at 
least partial resistance, M10I and N57S.  While the N57S mutant was previously 




Figure 26. Screening of viable CA library mutants for resistance to Mx2. (A) Screen 
indicating the level of infection, as compared to non-doxycycline treated controls, for 46 CA 
mutants (those viable in single cycle infectivity assays) in doxycycline treated MT-4 T-cells 
expressing doxycycline inducible Mx2. Multiple species variants of Mx2 were tested for 
resistance, as shown on the X-axis.  Mutants are represented by individual circles.  (B) The levels 
of infection for the 7 CA mutants conferring the greatest resistance to Mx2 identified in (A).  Viral 
titers were measured in MT-4 T-cells expressing doxycycline inducible Mx2 species variants with 
either WT (NHGcapNM) or CA mutants, in the presence of pre-treatment doxycycline, except in 





















































































































































































surprising result.  Intriguingly, this residue, like the residues in the cyclophilin 
binding loop, is a part of the cytosolic surface of mature CA that is known to be 
available to inhibitory interactions.  Furthermore, M10 and cyclophilin binding 
loop residues have been previously reported to be involved in escape from 
another antiviral factor, TRIM5α [140,219].  Outside of the N-terminal domain, 
there were two previously unreported mutants in the C-terminal domain that also 
conferred partial resistance to Mx2, M185I and E187V.  Interestingly, residue 
M185 is known to be involved in a vital hydrophobic contact at the CA 
dimerization interface [220].   As for mutant E187V, it appeared to convey only 
partial resistance to Hs and Mac Mx2, but gave nearly complete resistance to 
Agm Mx2 (Figure 26B).   
 When the seven mutant residues conferring resistance to Mx2 in the 
screen were mapped onto the capsid hexamer, a certain trend was apparent 
(Figure 27).  In general, residues conferring resistance were localized to very 
exposed surface areas.  This is perhaps not entirely surprising given the 
propensity for residues in the cyclophilin binding loop to be involved in Mx2 
escape, but it was intriguing that the trend also extended to the C-terminal 
exposed residues, and the N-terminal M10 residue.  The higher surface exposure 
of these residues within the mature CA hexamer may mean they are more 
accessible for direct interactions with host factors like Mx2.  As the CA library is 
not inclusive of mutants for all of the exposed surface residues, it is likely that 










Figure 27. CA mutant residues conferring Mx2 resistance typically occur in surface 
exposed regions of the CA hexamer.  The locations in the CA hexamer (PDB: 3GV2) of the 
seven residues identified in the CA-Mx2 resistance screen conferring the greatest degree of 
resistance are shown in green.  The image on the left shows the hexamer as viewed from the 
exterior of the intact conical capsid, the center image shows the hexamer from within the plane of 
the capsid lattice, and the rightmost image shows the hexamer as viewed from within the interior 











In summary, this screen of CA library mutants for Mx2 resistance highlights how 
valuable a resource the CA random mutants can be for probing functions and 
interactions with a variety of proteins and molecules. 
 
Chapter 6. HIV-1 IN and creation of a randomly mutagenized IN library to 
better understand genetic robustness and fragility 
6.1 Introduction to genetic robustness in HIV-1 IN  
 Having evaluated the robustness of HIV-1 CA, determined the biological 
basis for its extreme fragility, and investigated correlations between in vitro CA 
mutant fitness and in vivo occurrence, we were curious as to how unique CA’s 
fragility may be.  Satisfying this interest required evaluating the robustness of 
another HIV-1 protein in a similar manner.  Evaluation of the genetic robustness 
of another essential HIV-1 protein could also reveal more significant patterns 
about how competing selection pressures, such as those to both maintain 
structure and function, and to also diversify sequence to evade immune pressure, 
are likely to play out in other HIV-1 proteins. 
 Like HIV-1 CA, HIV-1 integrase (IN) is a highly conserved, essential, and 
multifunctional protein, and it is also the enzyme responsible for the integration of 
the viral genome into the host chromosome. It has previously been suggested 
that enzymes like IN may be particularly sensitive to mutation given their 
requirement to adopt and change their tertiary structure in very subtle and flexible 
ways [92].  The relatively highly conserved nature of IN also suggests it could be 
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vulnerable to substitutions [156].  Finally, the requirement for IN to interact with a 
number host factors, as is similarly true for CA, may also contribute to genetic 
fragility. 
 As the studies of CA robustness demonstrated, a protein’s structure can 
influence its genetic robustness.  While the X-ray crystal structure of the HIV-1 
intasome, the tetrameric dimer of dimer IN-viral DNA functional structure, has not 
yet been determined, the publication of the crystal structure of the prototype 
foamy virus (PFV) intasome [166,167] has provided further insight into the 
possible arrangement of HIV-1 IN’s domains within the tetramer.  It has also led 
to new and improved HIV-1 intasome models [164], one of which will be utilized 
in the subsequently described robustness studies [168].   
 Understanding the robustness of HIV-1 IN is particularly valuable given the 
highly beneficial clinical contributions integrase inhibitors have already made, and 
the further therapeutic potential IN holds [221].  In this second study of genetic 
robustness in HIV-1, the generation of an even larger unbiased mutagenesis 
library will be described, in which the in vitro robustness of HIV-1 IN and CA can 
be compared, and further analyzed in conjunction with the in vivo occurrence of 
IN mutants.  To this end, creation of a large, random IN mutant library will also 
permit the utilization of a recent HIV-1 intasome model in which it will be possible 





6.2 Comparison of IN and CA variability in vivo 
 In order for comparison of the robustness of HIV-1 IN and CA to be 
meaningful, it was necessary to establish, as quantifiably as possible, how 
similarly the two proteins might maintain mutations in vivo.  As robustness 
describes a tolerance to mutation, it seemed prudent to compare how frequently 
variants, introduced by reverse transcription or RNA polymerase II, actually 
appeared in separate cohorts of 1,000 HIV-1 subtype B sequences isolated from 
infected individuals for each protein.  By measuring the number of sequences 
that varied from the parental sequence at each residue in both proteins, it 
seemed possible to establish how similarly each protein might tolerate mutations. 
 When variation amongst the 1,000 HIV-1 subtype B sequences for CA and 
IN is mapped in a landscape fashion, CA and IN appear to have relatively similar 
mutation frequencies in vivo (Figure 28A, B).  The peaks denoting quite high 
variability from WT are present at comparable rates—around 9 individual 
residues in IN and 11 unique residues in CA contain at least 20% variation (such 
that of the 1,000 sequences for each protein, at least 200 sequences varied from 
the parental sequence at those distinct residues).  IN and CA also share a similar 
incidence for the residues indicating little or no variance.  The similarities 
between IN and CA variation are also particularly apparent when the frequencies 
of variants at a residue are arbitrarily binned (Figure 28C, D).  The percentage of 
residues with a given frequency range of variability differs between IN and CA the 





Figure 28. Comparison of naturally occurring variation in HIV-1 IN and CA.  (A, B) Survey of 
the frequency (%) of variants from WT that occurred at individual residues within 1000 HIV-1 
subtype B CA (A) or IN (B) isolates.  Residue position is shown on the X-axis from left (N-terminal 
residue) to right (C-terminal residue).  (C, D) The variability of IN and CA (as shown in A, B) 
binned such that the Y-axis indicates the percentage of residues within CA (C) or IN (D) with the 































































































CA residues and 19% of IN residues have this degree of variability.  Still, the 
percentage of residues with low (0-0.3%), intermediate (0.4-3%), and very high 
(>30%) variability is strikingly similar.  Ultimately, surveying the naturally 
occurring variation in IN and CA suggests that similar proportions of mutations 
are tolerated in vivo, implying that comparing IN and CA robustness is not only 
fitting, but an endeavor that may reveal similar degrees of fragility.   
6.3 Creation of the randomly mutagenized IN library 
 For construction of the randomly mutagenized IN library, the procedures 
were analogous to those used for generation of the CA library (Figure 29A, B).   
As before, a low fidelity PCR method, Genemorph II, was used to produce error-
prone IN encoding sequences.  These mutagenized sequences were digested 
and inserted into the replication competent clone, pNHGintBS, using the unique 
BstBI and SpeI restriction sites.  The pNHGintBS is nearly identical to the 
pNHGcapNM (accession: JQ686832) used for the construction of the CA library, 
and differs only by the creation of the BstBI site and reconstruction of the SpeI 
site to flank IN.  Like pNHGcapNM, pNHGintBS encodes EGFP in place of Nef, 
and it will hereafter be referred to as the parental or WT virus for experiments 
investigating IN, as will pNHGcapNM for experiments involving CA.   
6.4 Composition of the IN library, and comparison with the CA library 
 Subsequently during the IN library construction, around 770 single 
colonies were isolated and cultured, and proviral plasmid DNA was extracted and 








Figure 29. Generation, characterization, and comparison of the IN and CA randomly 
mutagenized libraries. (A) Schematic that illustrates the PCR-based mutagenesis of the 864 bp 
amplicon containing HIV-1 IN, which is flanked by BstBI and SpeI restriction sites.  Subcloning 
into the replication-competent proviral plasmid pNHGintBS followed Genemorph II mutagenesis of 
the amplicon.  (B) Schematic that illustrates the PCR-based mutagenesis of a 717 bp amplicon 
containing HIV-1 CA (and a few residues of MA), flanked by NotI and MluI restriction sites.  
Subcloning into the replication competent proviral plasmid pNHGintBS followed Genemorph II 
mutagenesis of the amplicon.  (C, E) Distributions of the number of nucleotide substitutions found 
in each clone in the IN (C) and CA (E) mutant libraries (including nonsense and duplicate 
mutations, mutations in MA and frameshifts).  (D, F) Distributions of the number of amino acid 
substitutions found in each clone in the IN (D) and CA (F) mutant libraries (including nonsense 






chromatograms that indicated the presence of more than one template, or that 
showed evidence of recombination, 683 clones remained, and the distribution of 
their nucleotide changes (Figure 29C) and amino acid substitutions (Figure 29D) 
was determined.  Comparing these IN library composition analyses with the 
distributions of CA library nucleotide changes (Figure 29E) and amino acid 
substitutions (Figure 29F) exposes the difference in the error or mutagenesis 
rates used during the creation of the two libraries.  Whereas the conditions for the 
CA library led to a single nucleotide change being the most frequent mutational 
outcome, the optimized lower mutagenesis rate utilized for the generation of the 
IN library meant far fewer clones had multiple nucleotide changes.  Thus, the IN 
library yielded more single nucleotide substitution clones from a smaller pool of 
clones.  Accordingly, this trend is reiterated in the distribution of amino acid 
substitutions (Figure 29D, F), and therefore the IN library included more mutants 
with single amino acid substitutions than the CA library.  It is these mutants that 
will be employed in the work described hereafter. 
 From the resulting single amino acid mutants in each library, additional 
clones were removed due to the presence of nonsense mutations, duplicate 
mutations of clones already in the library, frameshifts, or mutations outside the 
gene (only the case for the CA library, in which a very small fraction of matrix was 
in the mutagenized amplicon).  As a result, the final IN library contains 156 single 
mutants, which cover 118 (41%) of the 288 IN residues, and, as previously 
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described, the CA library contains 135 single mutants covering 102 (44%) of 
CA’s 231 residues. 
 
Chapter 7. Evaluations of IN library robustness and comparison with CA 
7.1 Fitness of single residue IN mutants 
 To compare the robustness of HIV-1 IN and CA, the fitness of single 
mutants was analyzed in two assays, as described and completed previously for 
the CA single amino acid mutants.  To briefly reiterate, in the single cycle 
infectivity assay, 293T cells were transfected with either WT or single residue IN 
mutant proviral plasmids, and the resulting virus-containing supernatant was 
added to MT-4 cells (at an MOI of ~1 for the WT virus), which were treated with 
dextran sulfate 16h post-infection to restrict infection to a single cycle.  
Alternatively, to measure replicative fitness, virus-containing supernatant 
harvested from WT or single IN mutant transfected 293T cells was added to MT-
4 cells in a much smaller dose (at an MOI of ~0.01 for the WT virus), after which 
multiple rounds of replication were permitted until the WT virus had infected 
>50% of cells (approximately 80 hours later) and the experiment concluded.  In 
both assays, fitness was calculated using the number of infected (EGFP-positive) 
cells, expressed as the percentage of the number of cells infected by the WT 
virus.  So as to distinguish between robust and fragile mutants in these assays, 
the same arbitrary cut-off for viability used for evaluating the CA library was again 
employed and generously set at 2% of parental virus fitness, below which it is 
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unlikely a virus would be able to thrive in vivo.  Since the replicative fitness assay 
incorporates a low-dose challenge and multiple replication cycles, this assay is 
likely a better determinant of how a mutant virus might behave in vivo, and for 
this reason, mutants with less than 2% of WT fitness in this assay were 
considered nonviable in evaluations of both the CA and IN libraries. 
 Considering the indispensable nature of HIV-1 IN, and its resemblance in 
variability to CA, it was surprising to discover that just 35% of single IN amino 
acid substitutions resulted in nonviable virus by the replicative fitness assay, 
whereas twice as many, 70%, of single CA amino acid substitutions were 
nonviable in the same assay.  The comprehensive list of the 101 viable IN 
mutations, with replicative fitness >2% of WT, can be found in Table 4, while the 
55 nonviable IN mutants can be found in Table 5.  The analogous single cycle 
and replicative fitness measurements are available for CA in Tables 1 and 2.  As 
was also true for CA, comparison of IN Tables 4 and 5 reveals how different 
substitutions at the same residue can sometimes result in vastly different fitness 
outcomes, as is the case for residue C65, indicating that the type of residue 
change can be important.  More often, however, multiple unique aa changes at 
the same residue resulted in relatively similar fitness.  Analysis of the role of an 
IN mutant’s type of residue change, with regard to hydrophobicity or molecular 
weight, in determining fitness did not reveal consistently significant trends (Figure 
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(% of WT)b 
E10D 91.5 107.9  Q148R 33.0 13.8 
E13V 78.4 93.9  I151T 32.4 12.0 
S17N 91.8 141.2  K156T 36.0 15.7 
P30H 9.5 3.9  K159M 44.7 29.5 
P30S 11.3 2.3  K160E 26.5 11.8 
K42I 71.8 71.2  I162T 6.0 3.1 
K42R 77.6 87.7  G163R 117.1 105.1 
A49V 77.4 79.9  Q164H 65.1 107.2 
M50I 89.3 75.2  D167E 92.6 132.9 
M50L 100.2 86.2  E170K 64.9 88.8 
M50V 80.6 71.1  L172F 91.0 143.4 
Q53L 63.9 39.7  T174I 44.3 57.9 
V54A 87.0 89.9  V176I 9.5 6.6 
D55E 45.4 30.3  V180I 51.6 63.6 
D55N 79.9 65.7  F181Y 68.3 95.1 
C56Y 108.6 91.1  H183Q 11.8 9.6 
G59E 95.2 65.0  G189E 24.6 8.6 
C65S 80.7 60.6  G197W 13.2 8.4 
L68S 94.2 103.6  E198Q 89.8 91.5 
V72D 35.9 15.6  I200M 85.5 98.5 
L74M 73.6 64.5  I203L 86.5 98.0 
V75I 99.7 73.4  I203M 101.5 101.5 
V75L 90.1 68.8  I204V 82.6 87.0 
V77I 82.5 56.8  A205S 84.3 79.0 
Y83H 77.9 52.5  T210I 45.3 44.6 
P90L 38.2 16.9  K211R 63.0 55.7 
P90Q 73.8 66.4  Q214E 79.1 79.1 
A91T 73.3 44.6  Q214H 79.0 54.8 
A91V 81.6 46.5  Q214L 13.5 5.2 
T93I 19.5 15.5  K215R 86.4 86.3 
Q95L 42.0 35.3  K215T 54.7 25.9 
L102F 18.2 13.3  Q216H 83.6 102.1 
T112I 92.9 61.8  N222I 14.8 5.8 
T112R 66.6 44.1  N222Y 85.2 93.8 
V113L 105.0 86.9  K236I 65.1 23.0 
T115I 18.1 7.9  K244N 39.7 21.4 
S119N 5.5 2.2  I251V 74.1 92.0 
S123N 54.6 40.4  Q252H 77.4 89.6 
S123T 13.5 3.3  S255I 87.1 70.1 
T124I 74.8 58.1  D256V 98.5 53.3 
T124S 110.1 94.2  I257L 77.0 65.3 
T125A 119.8 92.0  I257M 66.3 34.4 
V126F 86.9 82.9  I257V 79.0 48.7 
K127T 58.8 39.1  K258R 88.4 62.6 
A129S 36.1 28.6  P261S 102.0 85.8 
A129T 43.6 35.0  M275L 65.0 47.7 
A129V 20.3 9.6  G277S 67.3 49.8 
W131C 24.6 15.2  A282T 99.2 87.2 
Q137H 97.9 87.4  D286N 101.1 122.4 
E138D 103.7 90.4  D288G 107.8 86.4 
P145S 19.6 3.3     
Viable, or infectious, mutants were those with at least 2% of WT infectivity in the spreading replication assay. 
a Fitness measurement in which MT-4 cells were inoculated, at MOI=1 for the WT virus, with virus-containing 
supernatant from 293T cells transfected with single residue IN mutant proviral plasmids.  At 16h post-
infection, dextran sulfate was added to limit replication to a single cycle.  Values shown are the percentage 
of infected cells (GFP+) as compared to WT. 
b Measurement of infectivity in which MT-4 cells were inoculated, at MOI=0.01 for the WT virus, with virus-
containing supernatant from 293T cells transfected with single residue IN mutant proviral plasmids.  Multiple 
replication cycles were allowed over an 80h period.  Values shown are the percentage of infected cells 






Table 5. Nonviable HIV-1 IN mutants 
IN 
mutants 
G4E  N144I 
N18I  E152D 
K34E  N155Y 
V37E  V165L 
C40F  R166I 
G52R  M178V 
D64E  A179V 
C65F  I182M 
C65Y  I182N 
A76S  K188E 
A76T  K188N 
V77F  G192E 
H78L  A196G 
S81N  G197E 
I84V  G197R 
A86T  E198K 
A86V  D202E 
E87G  I204K 
L102S  E212D 
K103E  L213F 
W108R  R228W 
P109Q  K244I 
P109S  V249E 
V113A  I251K 
G118D  K258E 
W132C  K266N 
I135F  R269G 
I135T   
   
Mutants were considered nonviable if they had less than 2% of WT infectivity in the spreading replication 











Figure 30. Mutational fitness in IN and CA is not definitively determined by changes in 
hydrophobicity or molecular weight.   (A, B) Evaluation of the effect of mutant residue changes 
in hydrophobicity in IN (A) and CA (B) on fitness.  Figure legends indicate the abbreviations used 
to designate the initial hydrophobicity of a residue and the resulting change.  Analyses of 
disparities between conservative changes (i.e., polar (P) to polar (P)) and nonconservative 
changes (i.e., polar to nonpolar (NP)) were performed for all scenarios, and all significant 
differences are indicated. (C, D) Evaluation of the effect of molecular weight change in IN (C) and 
CA (D) library mutants on fitness.  Analyses between residue substitutions in which there was no 
change in molecular weight and those with either increases or decreases in molecular weight 













































































Type of residue change
NP = nonpolar
P = polar
PB = polar, basic



















































































PB = polar, basic












































































































substitution (see residues 34, 42, 78, 103, 166, 188, 228, 244, 258, 266, 269), 
perhaps because these residues are more likely to be involved in DNA binding 
[222], but were not entirely sensitive, as not all substitutions at polar basic 
residues resulted in significant differences in fitness (residues 127, 156, 159, 
160, 215, 236).  Overall, analyses of the fitness effects of the type of residue 
change in both the IN and CA libraries (Figure 30A-D) suggest that there are no 
overarching patterns that can determine how a substitution’s change in 
hydrophobicity or molecular weight will affect its fitness.  Together, the values 
provided in Tables 4 and 5 also provide an opportunity to make more general 
observations regarding IN domain fragility.  As Table 6 indicates, the CTD 
domain is notably more tolerant of mutation than the CCD or NTD. 
7.2 Distribution of IN fitness and divergence with CA fitness 
 The fitness measurements of IN differ from those of CA extensively.  As 
the distributions of mutational fitness effects (DMFE) measurements for IN and 
CA demonstrate, not only are there fewer mutants with severe fitness 
attenuations in IN, there are also more IN mutants with intermediate, small, or no 
fitness reductions, and this reinforces the notion that IN is more robust than CA 
(Figure 31A, B).   In many ways, IN mutant fitness distributions are similar to the 
DMFE measurements reported for other viruses, including RNA viruses, and this 
further strengthens the idea that capsid is unique in its extreme fragility 
[86,87,93].  In fact, whereas 89% of random CA single mutants caused >2-fold 






































affected by loss of 
infectiousness 
(%)e 
NTD 8 5 38 0 (0%) 6 (46%) 2 (15%) 0 (0%) 
CCD 69 42 38 9 (8%) 25 (23%) 11 (10%) 25 (23%) 
CTD 24 8 25 2 (6%) 3 (9%) 2 (6%) 5 (16%) 
IN total 101 55 35 11 (7%) 34 (22%) 15 (10%) 30 (19%) 
 
a The percentage of mutants considered nonviable (<2% of WT replicative fitness). 
b Mutants with at least 2-fold reductions in western blot virion IN expression. 
c Mutants with at least 2-fold reductions in western blot particle production, as measured by levels of p24 in virions. 
d Mutants with at least 2-fold reductions in western blot clathrin incorporation into virions. 






















Figure 31.  Distributions of mutational fitness effects in IN and CA.  (A, B) Distribution of 














































































































fitness of each IN and CA mutant is plotted against its linear position in the 
protein (for residues with multiple substitutions, the smallest fitness value is 
selected), differences in robustness are further highlighted (Figure 32A, B).  
These graphical representations expose stark disparities that exist between IN 
and CA robustness.  Integrase obviously includes significantly more high fitness 
mutants, including some with fitness levels above the parental virus.  Perhaps 
even more intriguingly, the higher levels of IN fitness in the linear landscape map 
relatively randomly, whereas CA tends to display small, localized regions of more 
relative robustness (corresponding largely to the β-strand, cyclophilin binding 
loop, interdomain linker region, and CTD helix 10) dispersed between regions of 
fragility. 
7.3 Structural analyses of IN fitness on an HIV-1 intasome model 
 As noted previously, mapping of viable and nonviable capsid mutants to 
the mature capsid hexameric structure revealed remarkable patterns in which 
viable mutants were preferentially localized to regions with greater solvent 
accessible surface area.  To determine if analogous patterns might exist for 
integrase mutants, IN library viability results needed to be mapped onto an 
integrase model structure.  Limited by the lack of crystal structure for the HIV-1 
intasome, the most recently published HIV-1 intasome model, based largely on 
the crystal structure of the PFV intasome, was employed to model the IN mutant 
library fitness results [168].  First, it was necessary to establish the location of the 







Figure 32. Comparison of linear fitness distributions throughout IN and CA sequences.  (A, 
B) Plots with replicative fitness, as the % of WT in a spreading infectivity assay, on the Y-axes, 
against the position of mutation on the X-axes, organized from left (N-terminal residue) to right (C-
terminal residue).  For individual residues in which the IN or CA library contained more than one 
mutation, the smallest fitness value is plotted, so as to represent any potential fragility that could 
be observed in nature.  For the IN mutants (A), the plot displays results shown in Tables 4 and 5, 




























































(Figure 33A).  In this structure, unique colors indicate the individual IN subunits, 
while grey regions designate DNA, and magnesium and zinc molecules are 
hidden from view.  Images, from left to right, model theoretical top, side, and 
underside profiles.  It should be noted that in this model, like the published HIV-1 
intasome models before it, the 2 outer subunits (in yellow and green) comprise 
only the CCD and a tiny portion of the CTD (including residues 50-230), while the 
inner subunits (red and blue) contain full-length IN [164,168]. 
 Upon mapping the nonviable IN mutants onto the HIV-1 intasome model 
structure two remarkable trends were apparent—the first was that the nonviable 
IN mutants appeared to be predominantly localized to the interfaces between IN 
subunits, in particular the dimerization interface between the inner and outer 
subunits (Figure 33A, B).  The second observation was that the nonviable IN 
mutants were generally more buried within the intasome structure (Figure 33A, 
B).  Mapping of the viable IN mutants onto the intasome model confirmed both of 
these observations, as viable mutants seemed to occur predominantly in surface 
locations, away from subunit interfaces (Figure 33C).  If the viable and nonviable 
IN mutants are mapped together on the same intasome structure, these trends 
are even more evident (Figure 33D).  To quantitatively verify the observation that 
viable residues appeared in more surface exposed positions, measurements 
were made for the solvent accessible surface area for each IN residue, in each of 
the four monomer subunits.  As Figure 33E conclusively illustrates, the nonviable 





Figure 33.  Mapping of IN mutant fitness on an HIV-1 intasome model.  (A) Images of an 
HIV-1 intasome model [168] showing the individual IN subunits comprising the tetramer.  Inner 
subunits are shown in red and blue, while outer subunits are in yellow and green.  Outer subunits 
model only the CCD, while the inner subunits include full-length IN.  Magnesium and zinc binding 
pockets are not visible, but DNA is shown in gray.  The image on the left shows the intasome as 
viewed from the top, the center image displays a side profile, and the rightmost image displays a 
view from underneath.  This intasome model will be utilized for all subsequent intasome images.  
(B) Locations of the nonviable (<2% of WT replicative fitness) IN mutants mapped on the 
intasome model.  (C) Locations of the viable (>2% of WT replicative fitness) IN mutants mapped 
on the intasome model.  (D) Locations of both viable and nonviable IN mutants mapped on the 
same intasome model.  (E) Analysis of the correlation between residue viability and solvent 
accessible surface area (in Å2). Mutated residues were either nonviable or viable, and 
corresponding solvent accessible surface area values for each IN subunit for every mutated 
residue were plotted, so as to represent the varying degree of surface exposure of individual 































values than the viable IN mutants (p=0.0002).  If the outer subunits of the model 
were to include full-length IN, it is likely this observation would only be further 
enhanced (given that many of the nonviable mutants are in the CCD, and if the 
outer subunits were to contain full-length IN, these nonviable mutants would likely 
be more buried by NTD and CTD arrangements, further lowering their solvent 
accessible surface area values). 
 
Chapter 8. Other functional impacts of IN mutations 
8.1 Characterization of IN mutant phenotypes by western blot  
 Measuring the in vitro fitness of the IN mutants was a good way of 
evaluating IN robustness, but there are other functional measures that could 
further inform its robustness in vivo.  Using western blot analyses, it was possible 
to quantify the effects of all 156 IN library single residue mutants on: particle 
production, IN expression in particles, and clathrin incorporation into particles 
(Figure 34).  Integrase mutants affecting all of these properties have already 
been reported, and it seemed prudent to investigate the extent of mutants that 
might exhibit such effects [186,209,223].  While the reasons for measuring 
particle production and IN expression in the IN mutants are more obvious, 
evaluation of clathrin incorporation is interesting as clathrin has previously been 
shown to help regulate proteolytic processing of HIV-1 virions during particle 
assembly, in a manner dependent on Pol, such that certain mutations in 





Figure 34. Analyses of the robustness of IN mutants by western blot.  Western blots of 
virions and cell lysates generated in 293T cells transfected with WT and IN mutant plasmids, and 
probed with anti-CA, anti-IN, and anti-clathrin heavy chain antibodies, as indicated.  Numbers 
shown below each band indicate the fluorescence intensities (LI-COR) associated with the WT or 
mutant IN protein that was pelleted from virion-containing supernatant.  Virion band blots shown 
below the anti-clathrin heavy chain (HC) are a secondary clathrin band appearing on the same 
blot, shown for correspondence to virion IN expression.  Mutant N18I likely lost the epitope for the 
anti-IN antibody, so this mutant was not included in Table 6 conclusions.  Phenotypes were 
considered reduced from WT if expression levels dropped by at least 2-fold. 
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Table 6 shows the summaries of the evaluated phenotypes, as observed by 
domain. 
 To begin more in-depth examination of these blots, it should be noted that 
cell-associated Gag expression in both the WT and all IN mutants revealed 
consistent levels of both capsid p24 and Gag precursor Pr55, ensuring 
transfection efficiencies should be equivalent, and giving confidence to the 
subsequent analyses.  More interesting is the observation that, consistent with 
the in vitro infectivity fitness measurements, only a minority of IN mutants 
appeared to have deficiencies by western blot.  In total, 34 (22%) mutants had at 
least 2-fold reductions in IN expression in virions, and just 13 (8%) had a more 
stringent 5-fold reduction (mutant N18I was not included in these calculations, as 
it seemed to have lost the epitope for the IN antibody).  Notably, a larger fraction, 
46%, of mutants in the NTD appeared to have substantial reductions in IN 
expression in virions than in the CCD (23%), while a far smaller proportion had IN 
expression reductions in the CTD (9%) (Table 6).  Additionally, mutants with 
decreases in IN expression often occurred in clusters in the CCD (residues 78-
83, 102-109, 129-132), suggesting certain, smaller regions of IN are particularly 
vulnerable in this regard.  Not surprisingly, the mutants with reductions in virion 
IN expression also had decreases in cell-associated IN expression as well.  
Similarly, there was a large degree of concurrence between the mutants with 
reductions in IN expression in virions, and those with diminished clathrin 
incorporation.  While not all mutants with IN expression reductions had clathrin 
 
 116 
incorporation reductions in virions, all mutants displaying reductions in clathrin 
incorporation also had reductions in IN expression in virions.  This was true for 
the traditional heavy chain clathrin band denoted HC (Figure 34), while a smaller 
clathrin band on the same blot often indicated comparatively lower levels of 
clathrin expression (Figure 34, below HC).  Still, there were no viable IN mutants 
with at least 2-fold reductions in virion clathrin incorporation, so there was no 
further investigation of the clathrin incorporation phenotype. 
 Very few IN library mutants appeared to display reductions in particle 
production.  Only 11 mutants (7%) had at least 2-fold decreases in virion-
associated p24, and none had the more stringent 5-fold reduction in p24.  
Interestingly, none of the mutants in the NTD had considerable reductions in 
particle production, nor were any affected by loss of infectiousness only, 
suggesting, not entirely surprisingly given past research, that this region is 
unlikely to contain many class II IN mutants.  Inspection of the mutants with 
significant (>2-fold) reductions in particle production also revealed that all of 
these mutants also had reductions in virion IN expression (Figure 34), but not all 
mutants with reductions in IN expression had reductions in particle production.  
Also intriguing is the observation that, of the 55 nonviable single amino acid IN 
mutants, 24 (44%) had no significant effect (< 2-fold) on either IN expression in 





8.2 Mapping of IN mutations with functional disruptions on an HIV-1 
intasome model 
 Given how informative the mapping of IN mutant viability on the intasome 
model had proved, it seemed worthwhile to investigate whether more structural 
trends could be illuminated by mapping the functional IN phenotypes observed by 
western blot onto the intasome model.  Strikingly, mapping of the nonviable 
mutants with at least 2-fold reductions in particle production exposed a rather 
narrow and distinct pattern in which most mutants displaying this phenotype 
congregated at the dimerization interface between the inner and outer subunits 
(Figure 35A).  This localization is particularly apparent when compared to the 
mapping of the nonviable mutants without IN expression or particle production 
reductions, the so-called ‘infectiousness only’ nonviable mutants, which were 
scattered throughout the intasome in a relatively buried fashion (Figure 35B).  
Equally remarkable was the mapping of the nonviable IN mutants with at least 2-
fold reductions in virion IN expression, in which an even greater number of 
mutants are localized to the same IN subunit interface region (Figure 36A), which 
is again especially clear when compared to the mapping of the nonviable 
‘infectiousness only’ mutants (Figure 36B).  The degree to which these nonviable 
mutants that had no reductions in either particle production or IN expression in 
virions occurred in buried locations in the intasome model was significant when 
compared to nonviable mutants with reduced IN incorporation (p=0.04) (Figure 







Figure 35. Localization of nonviable IN mutants affecting particle production in the 
intasome.  (A) Intasome model images showing the locations of the nonviable IN mutants shown 
by western blot to have at least a 2-fold reduction in particle production, as measured by levels of 
expression of p24 in virions.  (B) Intasome model images showing the locations of nonviable IN 
mutants for which western blot analyses indicated no significant reduction in either particle 
production (as measured by p24 expression in virions) or IN expression in virions.  These 

















Figure 36. Nonviable IN mutants disrupting IN expression in virions are also highly 
localized to IN subunit interfaces.  (A) Intasome model images showing the locations of the 
nonviable IN mutants shown by western blot to have at least a 2-fold reduction in IN expression in 
virions.  (B) Intasome model images showing the locations of nonviable mutants for which 
western blot analyses indicated no significant reduction in either particle production (as measured 
by p24 expression in virions) or IN expression in virions.  These nonviable mutants were affected 
only by a loss of infectiousness.  (C) Comparison of the solvent accessible surface area values 
(in Å2) for nonviable IN mutants that result in either a reduction in IN expression in virions, or no 
reductions in either virion IN expression or particle production (those mutant residues mapped in 
(B)).  All available subunit values were plotted for the relevant residues in each group.  




































than other nonviable IN mutants.  Together, the mapping on these intasome 
structures highlights surprising and novel findings indicating that nonviable IN 
mutations causing reductions in particle production and IN expression in virions 
are highly localized to certain IN subunit interfaces. 
 
Chapter 9. Analyses of IN library mutations in natural HIV-1 subtype B 
populations 
9.1 Occurrence of library IN mutations in an in vivo cohort and comparison 
with CA 
 As earlier demonstrated, the fragility of HIV-1 CA places tight constraints 
on the sequences of CA that naturally occur.  However, the relative robustness of 
HIV-1 IN indicates that IN may have more available sequence space to exploit.  
By utilizing the same cohorts of 1,000 HIV-1 subtype B IN and CA sequences 
used to evaluate the variability in Figure 28, the in vivo occurrence of the library 
IN and CA single amino acid mutants could be determined, and contrasted.  Plots 
of the frequency with which the IN and CA library mutations naturally occurred 
against the replicative fitness of the same mutants, revealed a number of 
similarities between the behavior of IN and CA mutants in vivo (Figure 37A, B).  
Remarkably, in both IN and CA plots, library mutants required the same amount 
of replicative fitness, at least 40% of WT, in order to occur at a frequency >1% in 
natural populations (Figure 37A, B).  Also notable was the observation that for 









Figure 37. Occurrence of library IN and CA mutations in natural HIV-1 subtype B 
populations.  (A, B) Plots indicating the frequencies with which IN (A) and CA (B) library single 
residue mutations occur in 1000 HIV-1 subtype B isolate IN and CA sequences (Y-axes) versus 
the replicative fitness of the same mutations (X-axes).  The horizontal dashed lines designate a 
frequency of 3%, above which mutations were considered to be frequently occurring.  Vertical 
dashed lines indicate 40% of WT replicative fitness, below which mutants typically occurred rarely 
in isolate sequences.  Mutants that had fitness values below 0.01% of WT, and that did not occur 










































or rarely (frequency <0.3%) appeared in vivo than occurred at a high frequency 
(>3%).  Table 7 lists the 11 fit IN mutants that occur frequently, and the longer list 
of 22 IN mutants that are equally fit, yet never occur in the 1,000 naturally 
occurring IN isolate sequences, along with their corresponding fitness values.   
Again, these results are surprising given the generally held notion that HIV-1 will 
take advantage of all available sequence space that does not incur significant 
fitness costs, and indicates that additional selective pressures may be at play for 
both IN and CA.  
9.2 Mapping of correlations between fitness, in vivo frequency, and 
variability on an HIV-1 intasome model 
 To explore whether the location of the fit (>40% WT replicative fitness) IN 
mutant residues correlated with the frequency with which they occur in vivo, 
intasome mapping was used to compare the locations of the subsets of ‘fit and 
frequent’ (>40% WT replicative fitness in vitro and >3% frequency in vivo) and ‘fit 
and never’ (>40% WT replicative fitness in vitro and 0% frequency in vivo) 
mutants.  Fit and frequently naturally occurring IN mutants appeared to be 
primarily localized in quite surface exposed locations throughout the intasome 
(Figure 38A).  Alternatively, the fit and never naturally occurring mutants were 
typically located in more buried positions throughout the intasome (Figure 38B).  
These observations were verified quantitatively by plotting the solvent accessible 
surface area values for each IN subunit residue for the fit ‘frequent’ and ‘never’ 





Table 7. Opposing frequencies of fit IN mutants in vivo 
Fit IN mutants 
occurring 










Fit IN mutants  
never occurring  




(% of WT)b 
E10D 107.9 8.7  E13V 93.9 
S17N 141.2 21.7  K42I 71.2 
M50I 75.2 9.7  A49V 79.9 
A91T 44.6 9.9  C65S 60.6 
T112I 61.8 3.8  V75I 73.4 
T125A 92.0 25.7  V75L 68.8 
D167E 132.9 3.1  Y83H 52.5 
I203M 101.5 3.5  P90Q 66.4 
K211R 55.7 17.4  S123N 40.4 
Q216H 102.1 3.1  V126F 82.9 
D286N 122.4 3.3  T174I 57.9 
    V180I 63.6 
    E198Q 91.5 
    I203L 98.0 
    Q214H 54.8 
    N222Y 93.8 
    Q252H 89.6 
    S2551 70.1 
    D256V 53.3 
    I257L 65.3 
    P261S 85.8 
    M275L 47.7 
    A282T 87.2 
a Fit mutants occurring frequently are those single residue mutants with fitness >40% of WT that are found in 
>3% of 1000 IN subtype B isolate sequences.  
b Spreading replication infectivity is as described in Table 4. 
c Frequency in subtype B isolates is as described in Figure 37. 














Figure 38. Residue surface exposure is a determinant of fit IN mutant frequency in vivo.   
(A) Intasome model images showing the locations of the fit (>40% of WT fitness) IN library 
mutations that occurred frequently (>3%) in 1000 HIV-1 subtype B IN isolate sequences.  (B) 
Intasome model images showing the locations of the fit (>40% of WT fitness) IN library mutations 
that never occurred in 1000 HIV-1 subtype B IN isolate sequences.  (C) Comparison of solvent 
accessible surface area values (in Å2) for the fit IN library mutants occurring either frequently (as 
shown in A) or never (as shown in B).  All available IN subunit solvent accessible surface area 
values were plotted for the individual ‘frequent’ or ‘never’ occurring fit mutants.  Significance was 




































residues are significantly more buried (p=0.004) (Figure 38C).  While the degree 
of surface exposure may not completely explain why some fit IN mutants seem to 
not occur in vivo, it appears to be a significantly contributing factor.  It is not 
entirely clear why more buried positions would be less tolerant to mutation in vivo 
in the absence of significant fitness effects.  It is possible that fit surface residues 
are more variable because their exposure makes them more vulnerable to 
unknown pressures, possibly of immune origin.  However, it may also be true that 
relatively small differences in fitness may still impact the frequency of certain 
mutations in vivo, as the average replicative fitness of the fit mutants that 
occurred frequently in vivo was 94.3% of WT, but the average replicative fitness 
of the fit mutants that never occurred in vivo was just 71.7% of WT.  
 Having established that the degree of surface exposure contributed to the 
naturally occurring frequency of IN library mutations, there was good reason to 
investigate whether the degree of surface exposure of IN residues might more 
generally explain why some residues are more variable than others in vivo.  
Again utilizing the cohort of 1,000 naturally occurring IN sequences, as well as 
the variability results found in Figure 28, residues for which isolate sequences 
varied from the parental sequence in more than 10% of sequences (variability 
>10%) were determined and mapped onto the intasome model (Figure 39A).  
Whereas these highly variable residues seemed to be preferentially localized to 
exposed locations, residues for which there was no variability observed appeared 






Figure 39.  HIV-1 IN natural variability is highly correlated with residue surface exposure.  
(A) Intasome model images showing the location of the residues in IN with >10% variability (as 
analyzed in 1000 HIV-1 IN subtype B isolate sequences, and indicated in Figure 28).  (B) 
Intasome model images showing the location of the residues in IN with no variants (as analyzed 
in 1000 HIV-1 IN subtype B isolate sequences, and indicated in Figure 28).  (C) Comparison of 
solvent accessible surface area values (in Å2) for the IN residues that were either highly variable 
(shown in A) or not variable at all (shown in B).  All available IN subunit solvent accessible 
surface area values were plotted for the relevant ‘>10% variability’ or ‘no variability’ residues.  





































again confirmed the observations, as residues with no variability had significantly 
lower values (p<0.0001) (Figure 39C).  Ultimately, within this HIV-1 intasome 
model, the degree of IN residue surface exposure seems to be a remarkably 
good indicator of both how fit a mutant is, and of how likely it is to occur in vivo. 
9.3 Summary of effects of IN mutations and comparison with effects of CA 
mutations 
 Having evaluated the robustness of HIV-1 IN both in vitro and in naturally 
occurring populations, in a fashion very similar to what was done for HIV-1 CA, it 
was possible to compare generalized predictions of the fate of randomly 
introduced nucleotide and amino acid substitutions into the two proteins, to better 
emphasize the stark differences in robustness.  For random nucleotide 
substitutions, an estimated 18% of IN substitutions and 22% of CA substitutions 
should result in synonymous changes, which should not, in most cases, 
significantly impact fitness.  The difference in the proportion of nucleotide 
substitutions yielding synonymous changes in IN and CA highlights how the 
composition of a protein can impact the outcome of any substitutions.  In the 
absence of any negative selection pressure other than fitness, then 43% of IN 
nucleotide substitutions, and a far smaller 10% of CA nucleotide substitutions, 
would be expected to result in nonsynonymous changes sufficiently replication 
competent (>40% of in vitro WT fitness) to, at least theoretically, thrive in vivo.  
Yet data from evaluations of the natural occurrence of the fit mutations with >40% 
of WT fitness (Figure 37) revealed that only a minority of these mutations actually 
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persist in vivo in both data sets, such that 12% of IN nucleotide substitutions, but 
only 4% of CA nucleotide substitutions would actually be expected to flourish in 
natural populations (Figure 40). 
 When only the nonsynonymous nucleotide substitutions are evaluated, 
then 40% of IN substitutions and 87% of CA substitutions would be expected to 
be nonviable, with only a few mutations in IN (5%), but most in CA (59%), 
inducing significant reductions in particle production (Figure 40).  This reinforces 
the idea that the basis for the genetic fragility of CA is the need to efficiently and 
correctly assemble particles, and that this requirement may be largely unique to 
CA.  While 60% of IN amino acid substitutions are sufficiently replication 
competent (at least 40% of WT fitness) to potentially thrive in vivo, the same is 
true for just 13% of CA amino acid substitutions, based on in vitro fitness 
measurements.  However, these numbers are significantly reduced by the finding 
that only a fraction of the intrinsically fit mutants actually persist in vivo (Figure 
37), such that 15% of IN amino acid substitutions and only 5% of CA amino acid 










Figure 40.  Diverse fates for random mutations in HIV-1 IN and CA.  Comparison of various 
likely outcomes for random nucleotide or amino acid substitutions in IN and CA, as indicated.  
Charts show changes that are synonymous (nucleotide substitutions only), nonsynonymous, and 
nonsense (as determined by using the pNHGintBS or pNHGcapNM sequences).  Substitutions 
that resulted in a stop codon were assumed to be nonviable while synonymous changes were 
assumed to be viable.  Given the observation that only mutants with >40% of WT in vitro fitness 
are observed in nature, this threshold was used as a sufficient determinant of mutants that would 
thrive in vitro (proportions of mutants with <40% WT fitness were determined using the viable and 
nonviable IN and CA mutants in Tables 1, 2, 4, and 5 and are denoted by red circumferential 
lines).  Ratios of fit mutants expected to thrive in vivo (nonsynonymous, viable in vitro and in 
vivo), or expected not to thrive (nonsynonymous viable in vitro only) were derived from data in 
Figures 22 and 37.  Fates of remaining mutants were determined using western blot data from 
Figures 19 and 34 (nonsynonymous, noninfectious particles or nonsynonymous attenuated 
particle formation (at least 5-fold deficit for CA and at least 2-fold deficit for IN)). 
CA Nucleotide substitutions Amino acid substitutions 
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As the circumstances contributing to the fragility of CA and the relative 
robustness of IN are likely to differ significantly, the situation of CA will first be 
addressed independently, followed by analyses of the comparative robustness of 
IN.  Thereafter, the implications about the genetic robustness and fragility of HIV-
1 proteins will be briefly discussed and given perspective. 
The extreme genetic fragility of HIV-1 CA 
 This study has sought to create a library of random CA mutations 
representative of those that occur naturally during HIV-1 infection, and to 
examine their biological effects.  In so doing, it has been possible to determine 
the genetic robustness of HIV-1 CA, and to correlate the effects of amino acid 
substitutions in vitro with their occurrence in natural viral populations.  
Furthermore, the creation of an extensive CA library constitutes an important 
resource for investigating various functions and properties of HIV-1 CA, including 
CA’s emerging impact on Mx2 retroviral restriction.  Importantly, the results have 
demonstrated the extreme genetic fragility of the HIV-1 CA protein, in which the 
majority (70%) of unbiased, single amino acid substitutions result in nonviable 
viruses (<2% of WT fitness). 
 In fact, after surveying the literature for all studies that have conducted 
mutagenesis in such a way that mutational robustness could be determined, HIV-
1 CA appears to be the most fragile protein ever described.  As Table 8 indicates, 





Table 8. Comparison of the robustness/fragility of HIV sequences* 
Protein/Domain Fragility# Author Summary/Notes 
HIV-1 capsid 70% Rihn et al. This study. 
HIV-1 protease flap 
region (aa 46-56) 
61% Shao et al. [224] 80 out of 131 mutants had negative 
activity, as shown by lack of Western 
blot p66/p51 bands. 
HIV-1 protease 54% Parera et al. [91] A total 86% of 107 single mutants 
were deleterious to catalytic 
efficiency, 54% lethal. 
HIV-1 protease 40% Loeb et al. [225] Out of 330 single missense mutants, 
around 40% were considered 
sensitive to mutation. 





28% Chao et al. [226] From 154 single mutants, 43 had RT 
levels that were ≤ 2% of WT. 
HIV-2 integrase 13% van den Ent et 
al. [227] 





12% Smith et al. [228] Using infectivity results, 3 out of 25 




0% van Opijnen et 
al. [90] 
None of the 15 single mutants 
diminished infectivity as much as 2 





0% Kim et al. [229] Fragility measured by genetic 
selection in E. coli, in which no WT 
aa were essential. 
 
*Table describes single residue mutagenesis studies that were (i) random (i.e. the cohort of 
mutants was not selected, and did not have amino acid bias) (ii) analyzed proteins or domains 
greater than 10 aa in length, and (iii) had datasets that included at least 5 mutants.  #Fragility, 
when not stated clearly in the published work, was deduced using the % of mutants either 
indicated as ‘lethal’ or that had 2% or less fitness or function compared to WT, using the available 
analyses of fitness or function utilized in the study.  In most cases, wording of summary/notes 







fragile protein, HIV-1 protease, only 40-54% of mutations resulted in nonviability 
[91,225].  HIV-1 CA is also more fragile than the small domains of HIV 
mutagenized because of their suspected severe fragility, such as the HIV-1 
protease flap region or the HIV-1 reverse transcriptase palm domain [224,226].  
Likewise, Table 9 demonstrates that HIV-1 CA is also more fragile than proteins 
or domains in viruses other than HIV, with human papilloma virus 16 protein E1, 
in which 63% of mutations were lethal, coming the closest to the fragility of 
capsid (although the study’s extremely small mutant sample size may 
overestimate its fragility) [230].  It is perhaps not surprising then, that CA is also 
more fragile than the whole viral genomes in which robustness has been 
evaluated (Table 10), in which 20-41% of mutations were lethal [87,93].  Viruses 
(particularly ss(+) RNA viruses) not only have very high mutation rates, but also 
have comparatively low tolerance to mutation [79,83], so it is again perhaps not 
unexpected that CA is more fragile even outside the viral context, as the most 
fragile nonviral protein described is the essential E. coli lac repressor, in which 
41% of residues were estimated to be intolerant of substitution [231] (Table 11, 
which is not inclusive of all nonviral random mutagenesis studies, but none were 
found that were more fragile). 
 While the biological basis of the extreme mutational fragility of the HIV-1 
CA appears to be the need to coordinate accurate and efficient assembly of 
particles (Figure 16-21), it is not immediately apparent why so many CA 
mutations result in reduced particle yields.  However, it seems likely that CA’s  
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Table 9. Comparison of the robustness/fragility of other viral sequences* 
Protein/Domain Fragility# Author Summary/Notes 
Human Papilloma Virus 
16 E1 
63% Yasugi et al. 
[230] 





constant region 4 
58% Morrison et al. 
[232] 
Only 11/26 single mutants were 
able to replicate appreciably. 
H3N2 influenza A 
hemaglutinin 
56% Nakajima et al. 
[233] 
44% of 248 single aa changes did 
not abrogate hemadsorption 
activity. 
H2N2 influenza A 
neuraminidase 
53% Yano et al. [234] 47% of 152 single mutations in NA 
were tolerated, certain regions 
were more sensitive. 
Bacteriophage λ Cro 53% Pakula et al. 
[235] 
Approximately 37 out of 70 single 




50% Rhee et al. [236] 4/8 single mutants had significant 
cell-free infectivity. 
Moloney murine 
leukemia virus capsid 
central domain 
40% Alin et al. [237] Virus replication was considered 
blocked based on RT levels for 6 
of 15 single mutants. 
Bacteriophage f1 gene 
V protein 
35% Terwilliger et al. 
[238] Masso et 
al. [239] 
139 out of 371 single point 
mutants were inactive (unable to 
inhibit E. coli growth). 
Varicella-Zoster virus 
thymidine kinase 
35% Suzutani et al. 
[240] 
Out of 17 single aa mutants, 6 




4-26% Eifan et al. [241] 5 /115 single mutants had ≤2% 
WT mini replicon activity, 30/57 
tested mutants had titers ≤2% of 
WT.  
Wheat streak mosaic 
virus HC-Pro 
24% Stenger et al. 
[242] 
6 out of 25 nonsynonymous 




16% Rennell et al. 
[243] 
From 2015 single aa substitutions, 
328 were deleterious enough to 
prevent plaque formation. 
Mason-Pfizer monkey 
virus capsid MHR 
15% Strambio-de-
Castillia et al. 
[244] 
2/13 single mutants have RT 
levels at ≤2% of WT, all other 
mutants maintain at least 50%. 
Adenovirus VI 9% Moyer et al. [245] Only 1 out of 11 random single 
mutants led to a greater than 10 
fold reduction in infectivity. 
Encephalomyocarditis 
virus internal ribosome 
entry site 
0% Van Der Velden 
et al. [246] 
Zero out of 13 single random 
mutants had significantly impaired 
in vitro translation. 









Table 10. Comparison of the robustness/fragility of viral genomes* 




41% Carrasco et al. [93] Out of 66 single mutants, 41% 





40% Sanjuán et al. [86] Fitness analysis of 91 single 
mutants showed a further 29% of 
mutants were deleterious 
Bacteriophage Qβ 29% Domingo-Calap et 
al. [87] 
29% of single mutations in 42 
clones of Qβ were considered 
lethal 
Bacteriophage f1  
(whole genome) 
24% Peris et al. [247] 24% of a total 51 single missense 
mutants were lethal.  Gene 
lethality varied 7 to 47% 
Bacteriophage 
ΦX174 
20% Domingo-Calap et 
al. [87] 
20% of single mutations in 45 
clones of ΦX174 were considered 
lethal 

















Table 11. Robustness/fragility measurements in nonviral proteins* 
ORF/Protein/Region Fragility# Author Summary/Notes 
E. coli lac repressor <41% Markiewicz et al. 
[231] 
From 4000 single mutants, authors 
conclude 192 of 328 aa should be 




34% Guo et al. [248] The calculated probability of a 
single random amino acid change 




33% Ihssen et al. [249] 16 of the 24 single mutants 
maintain strong PglB expression by 
ELISA 
Human interleukin-3 29% Olins et al. [250] From analysis of 770 mutants, 71% 
of residues were considered 





20% Holm et al. [215] 12 out of 61 single random mutants 
had zero enzyme activity 
TEM-1 beta-
lactamase 
16% Huang et al. [251] Authors conclude that 43 of the 263 
residues cannot tolerate 
substitutions 
T15 antibody heavy 
chain CDR2  
7% Chen et al. [252] Just 1 out of 15 single CDR2 
mutants lost binding function 
Barnase, a bacterial 
ribonuclease 
5% Axe et al. [253] 5% (of over 600 mutants) were 
found to render barnase wholly 
inactive 
Human interleukin-1α 2% Kawashima et al. 
[254] 
Only 1 out of 56 single mutants 
appeared to have significantly 
impaired activity 










fragility is related to the requirements that it maintain a structure that enables 
several different sets of interactions.  Within the mature hexameric CA lattice, 
each CA monomer must interact, via distinct interfaces, with at least three other 
CA monomers, and adopt a quite tightly constrained position with respect to its 
internal structure as well as other CA monomers within a hexamer [123].  At the 
same time, some CA monomers, that have precisely the same amino acid 
sequence, must be capable of assuming slightly different structures and positions 
relative to other CA monomers, in order to form the pentameric declinations that 
permit closure of the CA lattice [111,117].  Furthermore, another set of CA:CA 
interactions are likely required during the formation of immature virions [110].  
Beyond these constraints, the strength of the various CA:CA interactions in each 
of the different configurations probably needs to finely tuned to allow proper 
transitions from immature to mature virions during assembly, and appropriately 
timed disassembly of the capsid.  Indeed, earlier findings have suggested that 
proper capsid stability is required for HIV-1 infectiousness [255].  Additionally, CA 
interacts with numerous host proteins, including cyclophilin A [120], ABCE1 [119], 
and probably with CPSF6 [132] and nuclear pore complex proteins [131].  
Together, the number of CA interactions and functions, and the requirement for 
CA to adopt multiple different structures, and transition between them in an 
organized manner at multiple, critical stages of replication, likely places tight 
constraints on sequence and decreases the number of possible mutations that 
will not result in major fitness costs. 
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 While the lethal CA mutations could, in principle, affect any one of multiple 
steps in the HIV-1 life cycle, it appeared that most constitutively nonviable 
mutants exhibited attenuated particle formation.  Moreover, all of the conditionally 
nonviable ts mutants displayed attenuated particle formation at the 
nonpermissive temperature.  Interestingly, these deficits, at least for the 
conditionally nonviable mutants, could be rescued by inactivation of the viral 
protease.  Ultimately, these results indicate that the critical role of CA in 
coordinating efficient and accurate particle assembly, particularly during Gag 
proteolysis, is the principal cause of its genetic fragility.   
The processes of particle formation, budding and maturation are not yet 
fully understood, but over a relatively short period of time (5-6 minutes) [256], 
thousands of Gag and Gag-Pol molecules coalesce, in a manner requiring 
cleavage and rearrangement through regimented and ordered processes.  
Previous work has shown that incorrect, premature activation of the HIV-1 
protease can prevent particle formation [257].  Moreover, other perturbations of 
Gag (such as a partial nucleocapsid deletion) can attenuate particle formation in 
a way that is rescued by inactivation or inhibition of the viral protease [258,259].   
One idea that may explain these findings is that delayed particle formation may 
result in more extensive, or mistimed, proteolytic cleavage of Gag early in the 
assembly process, thereby attenuating particle formation [258,259].  Our finding 
that many of the constitutively nonviable and all of the conditionally nonviable CA 
mutants showed evidence of disrupted Gag processing, through the presence of 
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additional ~40 kDa protein species, is in accordance with the idea that CA 
mutations could similarly delay particle formation, resulting in mistimed Gag 
proteolysis relative to budding, and, thereby, protease dependent reductions in 
particle yields.  Within this framework, it is easier to understand how even subtle 
perturbations of Gag structure or multimerization, such as those caused by single 
amino acid substitutions, could disrupt the delicate process of HIV-1 assembly, 
and thus how critical a role CA plays in orchestrating virion morphogenesis.  
 Earlier work has shown that the N-terminal domain of HIV-1 CA is 
dispensable for particle formation [260], which is intuitively at odds with our 
finding that many mutations in the N-terminal domain result in diminished particle 
production.  However, it has already been hypothesized that misfolding of the N-
terminus (caused by small changes in CA) may be more disruptive to assembly 
processes than deletion [260].  Even without overt misfolding, inclusion of a CA 
NTD that does not fit correctly or efficiently into the hexameric lattice is likely to 
be more disruptive than NTD absence to the other interactions that are essential 
for particle formation (such as the CTD-CTD interactions). 
 Previous large-scale mutagenesis studies of retroviral CA proteins have 
utilized insertional mutagenesis of murine leukemia virus (MLV) CA (using 12 
amino acid peptide sequences) [261,262] and alanine substitution of surface 
exposed residues in HIV-1 CA [155].  The fact that the 12 amino acid insertions 
into MLV CA were uniformly lethal is consistent with the notion that retroviral CA 
proteins are generally intolerant of mutation, but insertions are obviously more 
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likely to disrupt CA structure than single amino acid substitutions.  In fact, a study 
of MLV CA mutants revealed that only 6 of 15 single amino acid substitutions 
(40%) in the central portion of CA were lethal [237].  Interestingly, this study 
found that the most frequent phenotype associated with single amino acid 
substitutions in MLV CA was the generation of noninfectious particles, instead of 
reduced particle formation, which suggests there may be a difference in the 
properties of MLV and HIV-1 CA proteins.  Prior to our study of HIV-1 CA, the 
most extensive mutagenesis study of HIV-1 CA [155] described 48 alanine-
scanning mutants that targeted surface exposed residues, of which 44% were 
nonviable.  This study also found that single mutations in both the NTD and CTD 
could cause attenuated or aberrant particle formation, as well as the generation 
of virions that appear morphologically normal, but were noninfectious [155].  The 
difference between the fraction of mutations that were lethal in [155] versus our 
study is in accordance with our finding that viable CA mutants tended to be 
confined to surface-exposed residues while mutations of the inner core of the CA 
structure were rarely associated with viability.   
 Most notably in relationship to the CA structure, we found that sequences 
encoding CA helices, particularly those in the NTD, were especially genetically 
fragile.  These sequences form the basic structure of the CA hexamer, and in 
some cases (helices 1, 2, and 3), are involved in the CA:CA interactions within 
the CA hexamers [123].  Mutations in the CTD helices, and in the interhelical 
loops (such as the cyclophilin A binding loop) were less likely to cause lethal 
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defects.  This comparative tolerance of mutations in certain portions of CA seems 
to correlate, at least partially, with conformational variation in crystal structures of 
CA hexamers [123].  In short, the CA NTD helices appear to be highly structurally 
constrained and particularly sensitive to mutations that might disrupt the shape or 
stability of the CA NTD monomer or the CA hexamer.   
 By correlating our CA library fitness measurements with analyses of the 
frequency with which the mutations occur in natural populations, we hoped to 
make observations that neither approach alone could reveal, and also make 
predictions about the outcomes of hypothetical mutations.  For example, all of the 
mutations that were present in our library at a frequency greater than 3% in 
natural populations (n=9) were relatively fit in vitro (>40% of WT fitness).  
Conversely, all the mutants with fitness <20% of WT (n=106) occurred at a 
frequency of <1% in natural populations.  Together, these findings indicate that 
there is indeed some correlation between fitness and occurrence in natural 
populations, and suggests that below ~40% fitness threshold, mutations are 
unlikely to confer a selective advantage in a human host.  Nevertheless, the 
correlation between mutant fitness and natural occurrence was not perfect, 
indicating that there are likely selective pressures other than fitness in vivo.  
Specifically, there was not complete concordance between fitness and Shannon 
entropy profiles in some portions of the CA sequence, and it was striking that less 
than half of the mutations that had little or no impact on fitness actually occurred 
in natural populations (‘fit but rare’ mutants).  These findings could be interpreted 
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as arising due to either the absence of a selective pressure driving the 
emergence of ‘fit but rare’ mutants, or alternatively, because of the presence of 
an unknown selective pressure against their emergence.  Importantly, in our 
examinations of the fit but rare mutants, we were unable to detect any defect in 
the ability of these mutants to infect primary cells, including primary T-cells and 
macrophages.  One possible explanation for these findings is that fit but rare 
mutants are eliminated from natural populations because they confer sensitivity 
to adaptive or innate immune responses.  Taken together, our findings suggest 
that only ~5% of all possible amino acid substitutions in CA result in viruses that 
can flourish in vivo. 
 One candidate for selective pressure that induces sequence variation in 
regions of high genetic fragility, and could possibly suppress ‘fit but rare’ mutants, 
is that imposed by cytotoxic T lymphocytes (CTLs).  Already a number of 
examples of CTL escape mutations in protective epitopes have been described, 
and these have been characterized by their predictability (reoccurrence of the 
same mutation in distinct infected individuals) [263], their impact on viral fitness 
(sometimes) [144,264], and by their co-occurrence with additional compensating 
mutations, suggesting an influence of epistatic interactions that might aid any 
compromised fitness induced by primary escape mutations [142,143].  These 
findings are in accordance with the finding that CA is extremely genetically 
fragile, and suggest that only a small number of possible mutations can permit 
escape from CTL responses and still maintain fitness.  At the same time, it is 
important to recognize that even though our library of CA mutants should be 
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representative of random variants, it is still only a sample of the possible 
mutations that can arise in CA in natural populations.  Previous analyses in cell 
culture indicate that a single cycle of HIV-1 replication (incorporating both 
transcription and reverse transcription) results in 1.4-3.4 x 10-5 mutations per 
nucleotide [79,80].  Within the 231 aa CA protein, this would yield approximately 
0.0097-0.023 errors per replication cycle, which is equivalent to an amino acid 
substitution once or twice per one hundred replication events.  Considering the 
large population size and high replication rate of HIV-1 in vivo [265], this means 
that every amino acid substitution that can occur by a single nucleotide 
substitution is generated in nearly every infected individual, many times each 
day.  Therefore selective pressures that are imposed in vivo can act on an 
enormous pool of possible variants.  The discrepancies between the fitness and 
Shannon entropy profiles (Figure 24A) suggest that even in regions of CA in 
which we found few or no fit mutants amongst 135 library mutants, there are still 
rare variants that can thrive in vivo, even if they may exhibit reduced fitness or 
require the co-occurrence of compensating mutations. 
 Previous work has shown that CTL responses to Gag, rather than other 
HIV-1 proteins, correlate best with reductions in viral loads, and thereby, often 
disease progression, during HIV-1 infection [148].  Interestingly, we observed 
that the so-called ‘protective’ CTL epitopes [143] were more likely to occur in 
regions of CA that were even more fragile than CA as a whole.  As Gag is among 
the most abundant viral proteins expressed in HIV-1 infected cells, this 
abundance, and the relative lack of plasticity in CA, likely contribute to the fact 
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that patients that display strong immune responses to Gag have comparatively 
favorable clinical outcomes.  Still, the capacity of viral populations to explore all 
available sequence space partly overcomes the genetic fragility of CA, and 
enables at least some amount of escape from immune responses, even those 
that target the most vulnerable regions of CA. 
 Aside from revealing significant insight into the genetic fragility of CA and 
its biological basis, the CA mutant library is also a useful tool for probing other 
HIV-1 functions and interactions with cellular factors.  Other members of the 
Bieniasz lab have previously utilized the single amino acid CA mutants to probe 
for mutants affecting: infection of non-dividing cells, resistance to TRIM5α, and 
interaction with cyclophilin A.  However, it has also been possible to now utilize 
the CA library to probe the emerging association between CA mutants and Mx2 
sensitivity.  While previous work had reported CA mutants conferring resistance 
to Mx2 restriction of HIV-1, these mutants were limited to only a few residues in 
the cyclophilin binding loop and one other residue (N57, already reported to 
impact infection of non-dividing cells) [136,137,138].  Surprisingly, we were able 
to identify CA mutations in multiple new regions of the CA protein that were able 
to confer resistance to Mx2, some of which had species-dependent effects.  
Interestingly, comparison of the mutant residues conferring resistance to Mx2 
and TRIM5α reveals significant similarities, often involving the same residues or 
precise mutations (such as M10I and P90T) [140,266].  Considering how many 
CA mutants have already been shown to impact a number of diverse HIV-1 
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functions and interactions with host factors, it seems likely that the CA mutant 
library will continue to prove a useful tool with which HIV-1 can be probed. 
 Recognizing and understanding the fitness effects of mutations in CA may 
facilitate drug or vaccine design.  For example, a recent study done in the context 
of a possible vaccination strategy revealed that mutations in the most conserved 
residues in CA are not necessarily associated with the highest fitness costs 
[267], as might otherwise be assumed.  Thus, an even better grasp of the 
constraints under which CA evolves may prove beneficial.  Furthermore, while 
CA has not yet been exploited as a target for drugs in the clinic, recent studies 
have indicated that it is, at least in principle, possible to do so 
[268,269,270,271,272].  Capsid’s genetic fragility should reduce, but not 
eliminate, the opportunities for drug resistance to occur, and it would thus be 
ideal if novel therapeutic treatments were to target the CA domains with the 
greatest fragility.  In spite of this, resistance to one recently identified CA-targeted 
inhibitor has already arisen in vitro through mutations in regions of CA that exhibit 
high fragility.  This is a testament to how the sheer number of variants that can 
be ‘tested’ or explored in natural viral populations, can, at least sometimes, 
overcome the lack of robustness in HIV-1 CA.  Nevertheless, the high genetic 
fragility exhibited by CA should make it a target of novel vaccination or therapy 
strategies. 
Uneven mutational robustness of HIV-1 integrase 
 In our second examination of genetic robustness in the context of HIV-1, 
we sought to examine the robustness of HIV-1 integrase, in a manner similar 
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enough to what was done with HIV-1 CA so as to permit comparison, and to also 
survey how the biological effects of IN mutations could be reflected in an HIV-1 
intasome model.  Using a large randomly mutagenized library of HIV-1 IN single 
amino acid mutants, we were able to determine the impact of single residue 
substitutions in vitro, observe their functional impact by western blot, correlate 
their fitness with their occurrence in natural viral populations, and, perhaps most 
importantly, meaningfully map all of these phenotypes onto an HIV-1 intasome 
model.  The results reveal a surprising, but significant juxtaposition between the 
robustness of IN and CA, with just 35% of individual amino acid substitutions in 
IN resulting in nonviable (<2% of WT fitness) viruses, whereas twice as many 
mutants in CA (70%) had the same effect.  This relative robustness is surprising 
given the expectation that essential enzymes will be fragile, but is notably similar 
to results published from a variety of other mutagenesis studies, many of which 
include other enzymes.  For example, comparisons of IN’s robustness with other 
mutagenized HIV-1 proteins (Table 8), reveals how similar the robustness of IN is 
to protease, in which 40% of single residue mutations were inactivating [225]. 
Furthermore, other viral proteins have been shown to be equivalently robust to IN 
(Table 9), such as bacteriophage f1 gene V and Varicella-Zoster virus thymidine 
kinase, in which 35% of mutations were inactivating [238,239,240].  In fact, the 
robustness of IN is also similar to several whole viral genomes (Table 10), 
including Tobacco etch potyvirus, vesicular stomatitis virus, and bacteriophage 
Qβ, in which 41%, 40%, and 29% of mutations were lethal respectively 
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[86,87,93].  Finally, the robustness of IN is comparable to nonviral enzymatic 
proteins (Table 11), such as 3-methyladenine DNA glycosylase (AAG), in which 
34% of single amino acid changes were calculated to be inactivating [248], and 
campylobacter jejuni oligosaccaryltransferase PglB, in which 33% of mutations 
appeared lethal [249].  While IN is more fragile than other HIV proteins and 
regions, such as the HIV-1 LTR, in which no mutations (0%) were significantly 
deleterious [90], or HIV-2 integrase, where just 13% of mutations could be 
considered lethal [227], HIV-1 IN’s relative robustness compared to CA validates 
the notion that the extreme fragility of CA is exceptional.  Nevertheless, the 35% 
of mutations causing lethal defects in HIV-1 IN are tremendously informative, as 
mapping to an HIV-1 intasome model indicated their fragility was unevenly 
distributed, with nonviable mutants, and particularly those affecting particle 
production or integrase incorporation or expression in virions, highly localized to 
precise subunit interface regions. 
 The reasons for the increased robustness of HIV-1 IN, as compared to 
HIV-1 CA, are not immediately apparent.  Both are relatively conserved proteins 
that are absolutely essential to viral replication, lack redundancy, and appear to 
have relatively similar rates of variability in vivo (Figure 28A-D), all of which could 
be hypothesized to make them equally vulnerable to mutation.  However, there 
are a number of dissimilarities that could underlie their divergent robustness.  As 
has been mentioned earlier, capsid must maintain a stable structure than can 
adopt a wide range finely tuned and delicately timed CA:CA interactions that 
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adjust between immature and mature conformations [110,123,255,256].  
Moreover, CA must also form interactions with a wide variety of host proteins, 
including nuclear pore complex proteins [131], cyclophilin A [120], and CPSF6 
[218].  While IN forms critical interactions with LEDGF [189], as well as 
interactions with TRN-SR2(TNPO3) [273] and 1/hSNF5 [274], and also 
undergoes multimerization processes [159], there have been no indications that 
these interactions or structural requirements are as numerous or as stringent as 
those required for CA.  Although any one interaction or structural requirement 
could theoretically contribute to the observation that significant fitness in CA 
occurs only within very limited regions, but occurs more frequently and randomly 
within IN, perhaps it is the larger number of specific and constrained CA 
interactions (both inter- and intra-protein) and requirements that limits viability to 
so few regions (Figure 32A, B).  Ultimately, it seems likely that the more 
numerous and restrictive requirements necessary for proper and efficient particle 
assembly, already established as the basis of HIV-1 CA fragility, result in a 
unique fragility for HIV-1 CA, and a relative robustness for IN that is more similar 
to other viral proteins.  With more studies of robustness in RNA viruses, more 
guidelines and critical determinants of robustness will become evident, although 
these are likely to vary by protein, as we have seen in this work. 
 Perhaps the most striking finding of the IN mutagenic analyses is the 
localization of many nonviable IN mutants to specific IN subunit interfaces within 
the intasome model.  Our intention in this work was not to reveal the significance 
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of single residues within IN, or to investigate IN catalytic activities, but rather to 
use the comprehensive nature of a randomly mutagenized IN library to derive 
more extensive understanding of the robustness of IN, and possible regions of 
vulnerability in the intasome.  For this reason, it was gratifying to observe how 
viable and nonviable mutants can be mapped to distinct regions in the intasome 
model (Figure 33A-D).  It was even more fascinating to observe how precisely 
many nonviable mutants affecting specific functional phenotypes, namely 
production of particles and IN expression in virions by western blot, can be 
mapped to certain subunit interfaces, while nonviable mutants affecting 
infectiousness only are scattered in buried positions, without any localized 
pattern in the intasome (Figures 35A, B and 36A, B).  Such strong and defined 
patterns suggest this HIV-1 intasome model is a valid structure for these 
analyses.  The location of most nonviable mutants impacting particle production 
or IN incorporation in virions lies at the interface between the inner (red and blue 
regions, Figure 33A) and outer (yellow and green regions, Figure 33A) IN 
subunits, approximately mutated IN residues 76-87, 102-113, 132-135, and 178-
213, and this is largely within the CCD-CCD dimerization interface [159].  
Interestingly, the outer subunits of the intasome have previously been reported to 
lack any clear role in formation of the tetramer, and their function has not been 
clear [159].  This may explain the considerable viability in these regions, although 
residues at the edges of the interface with the inner subunit clearly contribute 
significant fragility (Figure 33C, D).  While previous work has suggested that 
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individual residues at the inner-outer subunit, CCD-CCD interface could be 
important for multimerization [275,276], none has realized the full extent of the 
intolerance to mutation in this region, nor has there been intasome mapping that 
so clearly reveals these specific vulnerabilities.  However, this interface is 
adjacent to, and includes, some critical residues LEDGF uses to bind HIV-1 IN to 
affect multimerization [277].  This may explain why therapeutic allosteric 
integrase inhibitors (ALLINIs), which engage with IN at the same LEDGF binding 
sites (to prevent interaction), are effective at disrupting viral replication [202].  
Together, these data suggest that the nonviable IN mutants that affect particle 
assembly and IN expression in virions occur at localized regions within the CCD-
CCD interface on the intasome model, and their fragility may arise because they 
disturb critical multimerization or binding steps during the assembly of IN.  In 
many ways the suggestion that fragile IN residues are largely those affecting 
structural dimerization, multimerization, or binding, is analogous to the finding 
that fragile CA residues are typically those involved in assembly of particles.  
When combined, the data from both IN and CA suggest that specific structural 
interactions and requirements during assembly processes are amongst the most 
significant determinants of robustness and fragility. 
 While analysis of the location of the fragile IN mutants is informative, so 
too is the analysis of the robust, viable mutants.  An interesting commonality 
apparent between the IN and CA structural results is the observation that viable 
single residue mutants were more likely to occur in surface exposed locations 
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with higher solvent accessible surface areas (Figures 15A, C and 33C, E).  
Perhaps not intrinsically surprising, as similar data from as far back as the 1960s 
suggested haemoglobin residues at the surface were less sensitive to 
replacement than more internal residues [278], it is a trend that may be deserving 
of more recognition.  In the case of HIV-1 IN, these surface residues were also 
more variable (Figure 39 A, C), an observation that may also be true for other 
proteins under selective pressure, such as HIV-1 envelope [43,279,280], and 
which could be used as a predictor of residues more likely to be involved in IN 
therapeutic resistance.  Given the strong association between solvent accessible 
surface area and viability in both HIV-1 IN and CA, it is likely that the same 
association exists for other viral proteins, and it is possible that the amount of 
surface exposure, which could affect a number of structural interactions, is also a 
determinant of robustness.    
 Investigations of the relationship between the fitness of IN and CA library 
mutations and their frequency in naturally occurring HIV-1 subtype B populations 
revealed a remarkable shared threshold of 40% of WT replicative fitness, below 
which mutants were unlikely to occur frequently (>3%) in vivo (Figure 37A, B).  
This suggests such a fitness cut-off may exist for other viral proteins and that 
40% of WT may be an accurate estimate of in vivo fitness restrictions.  At the 
same time, we also noticed that while there were plenty of fit mutants that 
occurred frequently in natural populations, a large number of fit IN and CA 
mutants occurred either very rarely or never in our cohorts of 1,000 isolate 
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sequences (Figure 22C, Table 7).  This is intuitively at odds with the expectation 
that HIV-1 will take advantage of all available sequence space not severely 
impacting fitness.  Interestingly, the differential frequency of fit mutants can be 
explained for IN, at least in part, by the surface exposure of the fit IN ‘frequent’ or 
‘never’ mutants (Figure 38A-C).  Once again, those IN residues with greater 
surface exposure and higher solvent accessible surface area values were more 
likely to occur frequently, whereas more buried residues were more likely to 
never occur in isolate sequences (Figure 38A-C).  However, such an observation 
did not appear to be true for CA (results not shown), in which no significant 
differences could be detected between the solvent accessible surface area 
values for fit ‘frequent’ and ‘rare’ residues, although in CA’s case, the sample size 
for analysis was smaller.  As previously discussed, the immune pressure created 
by cytotoxic T lymphocytes (CTLs) could potentially suppress the ‘fit but rare’ CA 
mutations.  While both IN and CA have been documented to be under selective 
pressures created by host immune CD8+ CTL responses, there is little to no 
evidence of CTL-imposed reductions in replication capacity or viral load 
corresponding to Pol/IN, while multiple CTL responses to Gag/CA have been 
shown to reduce viral burdens [142,144,148,196,200,264].  The increased 
robustness of HIV-1 IN should mean it is less vulnerable to immune pressure, as 
it has more successful ‘escape’ options, and this may explain why ‘fit but rare’ 
mutations in IN are unlikely to be rare because of immune pressure.  Ultimately, it 
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is conceivable that multiple factors, including divergent ones in IN and CA, may 
contribute to the infrequency of some fit mutants in vivo.   
 The implications of the elevated robustness of HIV-1 IN are not entirely 
understood.  Less vulnerability to immune pressure is one likely outcome, and 
from a clinical standpoint, lower robustness of CA versus IN should help explain 
why individuals with immune responses to Gag during HIV-1 infection fare better 
than those with immune responses to other viral proteins [148].  Increased 
evolvability is also theorized to be positively correlated with higher robustness 
[82], as early experiments have already suggested [281]. 
Summary of HIV-1 IN and CA robustness and associated implications
 Through our evaluation of the genetic robustness of two necessary, but 
functionally divergent HIV-1 proteins, numerous common attributes were 
revealed.  Perhaps most interesting is the observation that in both proteins, 
fragile residues tended to be those critically involved in the formation of higher 
order structures—in CA, fragile residues typically impacted particle assembly in a 
manner likely dependent on CA:CA interactions, and in IN, fragile residues were 
largely localized to regions associated with multimerization.  While perhaps not 
inherently surprising, this observation may inform of residues or regions in other 
viral proteins that could be similarly vulnerable to mutation.  At the same time, 
and in accordance with Perutz’s 1968 suggestion [278], we also noted that the 
fragile residues in both IN and CA tended to be those in more buried locations, 
with lower solvent accessible surface area values.  Together, this suggests that, 
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generally speaking, residues in more buried positions are likely crucial to the 
structural integrity of the protein, such that disruption by substitution can be a 
lethal blow to assembling multimers.   Finally, we observed a rather surprising 
shared cutoff for mutant viability in vivo: in analyses of both IN and CA libraries, 
mutants required almost exactly 40% of WT fitness in vitro in order to occur 
frequently in natural populations (>3%).  This alludes to the presence of a 
common threshold at which mutations can confer a selective advantage, and 
such a limit may also apply to single amino acid substitutions in other HIV-1 open 
reading frames, or even other viruses.  Evaluation of these similarities provides 
the beginning of a framework in which new structural or functional commonalities 
amongst viral proteins might be uncovered. 
Nevertheless, our genetic robustness studies often revealed significant 
differences between IN and CA.  Most obviously, the two differ greatly in their 
degree of genetic fragility, with 70% of random single amino acid substitutions in 
CA resulting in nonviability, while only 35% of single amino acid substitutions in 
IN had the same effect.  The comparative robustness of IN was unexpected 
given that IN is highly conserved, essential, required to adopt variable 
conformations, and shows variability similar to that of CA in vivo.  However, as 
we have already discussed, the differences in the fragilities of IN and CA likely 
reflect each protein’s individual requirements for inter- and intra- protein 
interactions.  In turn, it seems likely that the disparities between IN and CA’s 
fragilities also underlie the differences in each protein’s susceptibility to immune 
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pressures, including those imposed by CTLs.  Ultimately these differences are 
significant, as they indicate that particularly fragile proteins, like HIV-1 capsid, 
may be better targets of novel therapies than more robust proteins.  Furthermore, 
the distinctions between IN and CA highlight how further genetic robustness 
studies of additional proteins in HIV-1 might fill in the significant gaps surrounding 
our understanding of HIV-1’s evolutionary capacity. 
Understanding the genetic robustness and fragility of individual proteins in 
HIV-1, like IN and CA, advances our basic understanding of HIV-1 and reveals 
how its proteins uniquely cope with pressures induced by high mutation rates and 
a hostile host environment.  Additionally, evaluation of genetic fragility provides 
insight that could help predict: vulnerable regions within protein structures that 
could be targeted by novel inhibitors, constraints on sequence space, and 
resistance to therapeutic treatments.  This may prove vital to better estimating 
the evolutionary path of viruses like HIV-1, and may also aid the development of 
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